WO1997030662A1 - Method for making and/or repairing cartilage - Google Patents
Method for making and/or repairing cartilage Download PDFInfo
- Publication number
- WO1997030662A1 WO1997030662A1 PCT/US1997/002909 US9702909W WO9730662A1 WO 1997030662 A1 WO1997030662 A1 WO 1997030662A1 US 9702909 W US9702909 W US 9702909W WO 9730662 A1 WO9730662 A1 WO 9730662A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- scaffold
- cells
- stromal cells
- tissue
- fact
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
- A61L27/3654—Cartilage, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3852—Cartilage, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/30199—Three-dimensional shapes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
- A61F2002/30766—Scaffolds for cartilage ingrowth and regeneration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
- Y10S623/902—Method of implanting
Definitions
- the present invention relates to methods for making and/or repairing cartilage in vivo. More specifically, the invention relates to methods of making and/or repairing cartilage comprising implanting into a patient, at a site of cartilage damage or loss, a biocompatible, non-living three- dimensional scaffold or framework structure, in combination with periosteal/perichondrial tissue, and administering a preparation of chondrocytes and/or other stromal cells, such as chondrocyte progenitor cells, to the site of the implant before, during or after implantation of the scaffold and/or the periosteal/perichondrial tissue.
- the periosteal/perichondrial tissue can be used to hold the scaffold in place at the site of implantation and also provides a source of stromal cells, e.g., chondrocytes and/or chondrocyte progenitor cells, for attachment to the scaffold in vivo.
- stromal cells e.g., chondrocytes and/or chondrocyte progenitor cells
- the preparation of stromal cells seeded directly into the implantation site in vivo provides not only a readily-accessible source of chondrocytes and/or other stromal cells for attachment to the scaffold but also provides a rapid and efficient means of inducing chondrogenesis as well as migration of stromal cells from the surrounding in vivo environment to the scaffold via factors produced by the stromal cells of the preparation.
- the seeded stromal cells can be genetically engineered to express gene products beneficial to growth, implantation and/or amelioration of disease conditions. The methods of the invention therefore result in the efficient production
- the methods of this invention are useful in the production/repair of articular cartilage in patients suffering from degenerative connective tissue diseases such as rheumatoid and/or osteoarthritis as well as in patients who have cartilage defects due to trauma.
- the methods of this invention can be used to replace or augment existing cartilage tissue, to introduce new or altered tissue or to join together biological tissues or structures.
- cartilage e.g., articular or hyaline cartilage, elastic cartilage and fibrocartilage.
- Articular cartilage is found at the articular surfaces of bones, e.g., in the joints, and is responsible for providing the smooth gliding motion characteristic of moveable joints. Articular cartilage is firmly attached to the underlying bones and measures less than 5mm in thickness in human joints, with considerable variation depending on joint and site within the joint.
- articular cartilage is aneural, avascular, and alymphatic. In adult humans, this cartilage derives its nutrition by a double diffusion system through the synovial membrane and through the dense matrix of the cartilage to reach the chondrocyte, the cells that are found in the connective tissue of cartilage.
- articular cartilage consists of highly specialized chondrocyte cells surrounded by a dense extracellular matrix consisting mainly of type II collagen, proteoglycan and water. While the biochemical composition of articular cartilage includes up to 65-80% water (depending on the cartilage) , the collagen component of the cartilage is the most prevalent organic constituent.
- the collagen (mainly type II) accounts for about 15-25% of the wet weight or about half the dry weight, except in the superficial zone where it accounts for most of the dry weight. Its concentration is usually progressively reduced with increasing depth from the articular surface.
- the proteoglycan content accounts for up to 10% of the wet weight or about a quarter of the dry weight.
- Proteoglycans consist of a protein core to which linear sulfated polysaccharides are attached, mostly in the form of chondroitin sulfate and keratin sulfate.
- articular collagen contains several other collagen types (IV, V, IX and X) with distinct structures.
- IV, V, IX and X collagen types
- chondrocytes Induction of cartilage matrix degradation and proteinases by chondrocytes is probably induced primarily by interleukin-1 (IL-1) or tumor necrosis factor- ⁇ (TNF- ) (Tyler, 1985, Bioche . J. 225:493- 507) .
- IL-1 interleukin-1
- TNF- tumor necrosis factor- ⁇
- the current therapy for damage or loss of cartilage is replacement with a prosthetic material, for example, silicone for cosmetic repairs, or metal alloys for joint realignment.
- Implantation of prosthetic devices is usually associated with loss of underlying tissue and bone without recovery of the full function allowed by the original cartilage. Serious long-term complications associated with the presence of a permanent foreign body can include infection, erosion and instability.
- Use of sterilized bone or bone powder or surgical steel seeded with bone cells that are eventually implanted have been largely unsuccessful because of the non-degradable nature of the cell support.
- fibroblasts are exposed in vitro for a minimum of three days to a soluble bone protein capable of stimulating a chondrogenic response.
- the activated fibroblasts are then transferred in vivo by combining them with a biodegradable matrix or by intra-articular injection or attachment to allografts or prosthetic devices.
- the disadvantage of this method is that chondrogenesis is not allowed to develop in the short-term cultures and there is an unduly heavy reliance on cartilage synthesis by the exposed fibroblasts at the implant site. See Caplan, A., United States Pat. No. 4,609,551, issued September 2, 1986. United States Pat. No. 5,041,138 to J.P. Vacanti et al.. issued August 20, 1991, describes the growth of cartilaginous structures by seeding chondrocytes on biodegradable matrices in vitro for subsequent implantation in vivo.
- United States Patents Nos. 5,197,985 and 5,226,914, to Caplan et al.. issued March 30, 1993 and July 13, 1993, respectively, relate to culturing marrow-derived mesenchymal stem cells in vitro in the presence of growth factors, applying these cells to a carrier, e.g., a porous ceramic vehicle, to promote round cell morphology, and implanting the carrier containing the cells into damaged articular cartilage.
- a carrier e.g., a porous ceramic vehicle
- Biomaterials 14 (No. 7): 513-521 relate to the use of free autogenous periosteal grafts that are placed directly into full-thickness articular defects for the repair of such defects in animals.
- the present invention relates to methods of making and/or repairing cartilage in vivo comprising implanting into a patient, at a site of cartilage damage or loss, a biocompatible, non-living three-dimensional scaffold or framework structure in combination with periosteal/perichondrial tissue that can be used to hold the scaffold in place and provides a source of chondrocyte progenitor cells, chondrocytes and other stromal cells for attachment to the scaffold in vivo.
- a preparation of cells that can include chondrocytes, chondrocyte progenitor cells or other stromal cells is administered, either before, during or after implantation of the scaffold and/or the periosteal/perichondrial tissue; the cells are administered directly into the site of the implant in vivo and promote chondrogenesis and the production of factors that induce the migration of chondrocytes, progenitor cells and other stromal cells from the adjacent in vivo environment into the scaffold for the production of new cartilage at the site of implantation.
- the three-dimensional scaffold contains interstitial spaces into which progenitor cells, chondrocytes and other stromal cells from the adjacent in vivo environment, including the implanted periosteal/perichondrial tissue, migrate for attachment and growth on and within the scaffold structure.
- the preparation of stromal cells seeded in combination with the scaffold and periosteal/perichondrial tissue provides a ready source of chondrocytes and other stromal cells which produce biological factors that promote chondrogenesis and the migration of stromal cells from, e.g., the periosteal/perichondrial tissue to the scaffold for attachment and/or differentiation thereon.
- the stromal cell preparation also provides a direct source of stromal cells, e.g., chondrocytes and/or progenitor cells, that are capable of migrating into the scaffold and attaching thereto.
- stromal cells e.g., chondrocytes and/or progenitor cells
- the stromal cells in the scaffold whether derived from the periosteal/perichondrial tissue, from the exogenous stromal cell preparation or from the in vivo environment adjacent to the implant site, grow on the scaffold to form a cellular matrix and provide the support, growth factors and regulatory factors required for cartilage formation at a cartilage defect site in vivo.
- the methods of this invention thus result in the production of new cartilage in vivo at the implant site.
- the periosteal/perichondrial tissue is placed over the implanted scaffold at the site of cartilage damage or loss ("the defect site") and affixed, e.g. , by sutures, to that site, thus holding the scaffold in place.
- the scaffold is composed of a biodegradable material such that, upon successful engraftment, the scaffold structure is completely absorbed in vivo, resulting in new cartilage having no foreign, non ⁇ living material encompassed within it.
- the preparation of chondrocytes and/or other stromal cells is administered in vivo to the site of the implant after the scaffold and periosteal/perichondrial tissue have been implanted.
- bioactive agents such as cellular growth factors (e.g. , TGF- ⁇ ) , factors that stimulate chondrogenesis (e.g., bone morphogeni ⁇ proteins (BMPs) that promote cartilage formation) , factors that stimulate migration of stromal cells and/or matrix deposition, anti-inflammatories or immunosuppressants, are included at the implantation site.
- these factors can be incorporated into the scaffold material to provide for release at the site of implantation; the scaffold can also be comprised of, or coated with, one or more of these bioactive agents.
- the factor(s) can be administered into or adjacent to the scaffold, either before, during or after seeding of the stromal cells, e.g., the bioactive agent(s) can be administered to the site, either as a separate preparation or as part of the stromal cell preparation.
- the stromal cells seeded at the defect site can be genetically engineered to express the genes for these bioactive agents, e.g. , specific types of TGF- ⁇ such as TGF-S1 or specific types of BMPs such as BMP-13. Exposure of the defect site to these bioactive agents promotes the successful and/or improved production of new cartilage and/or improves the success of implantation, for example, by reducing the risk of rejection or inflammation associated with the implant.
- the stromal cells can be genetically engineered to express an i-inflammatory gene products to ameliorate the effects of degenerative diseases like rheumatoid arthritis which result in cartilage damage due to inflammatory reactions; e.g. , the stromal cells can be engineered to express peptides or polypeptides corresponding to the idiotype of neutralizing antibodies for granulocyte- macrophage colony stimulating factor (GM-CSF) , tumor necrosis factor (TNF) , interleukin-2 (IL-2) , or other inflammatory cytokines and mediators.
- GM-CSF granulocyte- macrophage colony stimulating factor
- TNF tumor necrosis factor
- IL-2 interleukin-2
- the stromal cells can be genetically engineered to express tissue factors that enhance migration of stromal cells from the adjacent in vivo environment into the scaffold at the implantation site.
- the cells are engineered to express such gene products transiently and/or under inducible control during the post-operative recovery period, or as a chimeric fusion protein anchored to the stromal cell, e.g. , a chimeric molecule composed of an intracellular and/or transmembrane domain of a receptor or receptor-like molecule, fused to the gene product as the extracellular domain.
- the stromal cells can be genetically engineered to "knock out" expression of factors that promote rejection of the implant or degenerative changes in articular cartilage due to aging, rheumatoid disease or inflammation.
- factors that promote rejection of the implant or degenerative changes in articular cartilage due to aging, rheumatoid disease or inflammation For example, expression of pro- inflammatory mediators such as GM-CSF, TNF, IL-1, IL-2 and cytokines can be knocked out in the exogenously-administered stromal cells or on the implanted periosteal or perichondrial tissue to reduce the risk of inflammation.
- the expression of MHC class II molecules on the cells or tissues can be knocked out in order to reduce the risk of rejection of the implant.
- the methods of the invention may afford a vehicle for introducing genes and gene products in vivo to assist or improve the results of the implantation and/or for use in gene therapies.
- genes that prevent or ameliorate symptoms of degenerative changes in cartilage such as rheumatoid disease or inflammatory reactions and bone resorption may be underexpressed or overexpressed in disease conditions and/or due to aging.
- the level of gene activity in the patient may be increased or decreased, respectively, by gene replacement therapy by adjusting the level of the active gene product in genetically engineered stromal cells.
- the cartilage defect site into which the implant will be placed is treated, preferably prior to implantation, to degrade the pre-existing cartilage at the defect site, freeing cells to migrate into the scaffold of the implant and promoting the orderly deposition of new cartilage.
- Methods of such treatment include enzymatic treatment, abrasion or microdrilling.
- the preparation of stromal cells of the invention can be injected into the degraded cartilage at the defect site, e.g., into the surrounding cells or into the walls of the defect, providing a source of biological factors that induce migration of stromal cells from the degraded cartilage to the implant.
- the present invention involves methods of making and/or repairing cartilage in vivo comprising the implantation in vivo of a three-dimensional scaffold or framework structure made of a biocompatible, non-living material in combination with periosteal/perichondrial tissue and the administration of a preparation of stromal cells, such as chondrocytes or chondrocyte progenitor cells, which cells are seeded at the site of implantation in vivo.
- stromal cells such as chondrocytes or chondrocyte progenitor cells
- chondrocyte progenitor cell refers to either (1) a pluripotent, or lineage-uncommitted, progenitor cell, typically referred to in the art as a “stem cell” or “mesenchymal stem cell”, which is potentially capable of an unlimited number of mitotic divisions to either renew its line or to produce progeny cells which will differentiate into chondrocytes; or (2) a lineage-committed progenitor cell produced from the mitotic division of a stem cell which will eventually differentiate into a chondrocyte.
- the lineage- committed progenitor is generally considered to be incapable of an unlimited number of mitotic divisions and will eventually differentiate into a chondrocyte.
- cartilage or “cartilage tissue” as used herein is generally recognized in the art, and refers to a specialized type of dense connective tissue comprising cells embedded in an extracellular matrix (ECM) (see, for example, Cormack, 1987, Ham's Histology, 9th Ed., J.B. Lippincott Co., pp. 266-272) .
- ECM extracellular matrix
- the biochemical composition of cartilage differs according to type; however, the general composition of cartilage comprises chondrocytes surrounded by a dense ECM consisting of collagen, proteoglycans and water.
- cartilage Several types are recognized in the art, including, for example, hyaline or articular cartilage such as that found within the joints, fibrous cartilage such as that found within the meniscus and costal regions, and elastic cartilage.
- the production of any type of cartilage is intended to fall within the scope of the invention.
- the invention is directed predominantly to methods for the production of new cartilage tissue in humans, the invention may also be practiced so as to produce new cartilage tissue in any mammal in need thereof, including horses, dogs, cats, sheep, pigs, among others. The treatment of such animals is intended to fall within the scope of the invention.
- the invention is divided into the following sections solely for the purpose of description: (a) the three- dimensional scaffold; (b) the periosteal/perichondrial tissue and its implantation in combination with the scaffold; (c) the stromal cell preparation, including genetically engineered stromal cells; (d) administration of the stromal cells in vivo and (e) uses of the methods of the invention.
- the three-dimensional scaffold or framework structure may be of any material and/or shape that: (a) allows cells to attach to it (or can be modified to allow the cells to attach to it); and (b) allows cells to grow in more than one layer. Because the three-dimensional structure is to be implanted in vivo, it may be preferable to use biodegradable materials such as polyglycolic acid (PGA) , polylactic acid (PLA) , hyaluronic acid, catgut suture material, gelatin, cellulose, nitrocellulose, collagen, cotton, or other naturally- occurring biodegradable materials.
- PGA polyglycolic acid
- PLA polylactic acid
- catgut suture material gelatin
- gelatin cellulose
- nitrocellulose collagen, cotton, or other naturally- occurring biodegradable materials.
- the three-dimensional structure prior to implantation, e.g., by treatment with ethylene oxide or by gamma irradiation or irradiation with an electron beam.
- a number of other materials may be used to form the scaffold or framework structure, including but not limited to: nylon (polyamides) , dacron (polyesters) , polystyrene, polypropylene, polyacrylates, polyvinyl compounds (e.g., polyvinylchloride) , polycarbonate (PVC) , polytetrafluorethylene (PTFE, teflon) , thermanox (TPX) , and a variety of polyhydroxyalkanoates.
- nylon, polystyrene, etc. may be poor substrates for cellular attachment, when these materials are used as the three-dimensional framework, it is advisable to pre-treat the framework prior to implantation in order to enhance the attachment of chondrocytes and other stromal cells to the scaffold.
- nylon matrices can be treated with 0.1 M acetic acid and incubated in polylysine, PBS, and/or collagen to coat the nylon.
- Polystyrene could be similarly treated using sulfuric acid.
- any of the above-listed materials may be formed into a mesh or a felt, for example, to produce the three-dimensional framework or scaffold for use in the methods of this invention.
- the openings of the framework should be of an appropriate size to allow the chondrocytes and other stromal cells to stretch across the openings. Maintaining actively growing stromal cells which stretch across the framework enhances the production of growth factors which are elaborated by the stromal cells, and further enhances new cartilage formation in vivo.
- the openings of the framework must allow for adequate diffusion of nutrients and waste products into and out of the structure and for vascularization at the site of implantation.
- the stromal cells may rapidly achieve confluence but be unable to easily exit from the matrix; trapped cells may exhibit contact inhibition and cease production of the appropriate factors necessary to support proliferation. If the openings are too large, the stromal cells may be unable to stretch across the opening; this will also decrease stromal cell production of the appropriate factors necessary to support proliferation.
- openings ranging from about 150 ⁇ m to about 220 ⁇ m are satisfactory. However, depending upon the three- dimensional structure and intricacy of the framework, other sizes may work equally well. In fact, any shape or structure that allows the stromal cells to stretch and continue to replicate and grow for lengthy time periods will work in accordance with the invention. For example, for felt-type frameworks, openings ranging from about 80 ⁇ m to about 120 ⁇ m are preferred.
- the scaffold is a felt, which can be composed of a multifilament yarn made from a bioabsorbable material, e.g., PGA, PLA, polygluconate (PLGA) or hyaluronic acid.
- the yarn is made into a felt using standard textile processing techniques consisting of crimping, cutting, carding and needling.
- the porosity of the felt ranges from 80-98%, the density of the felt ranges from 30-60 mg/cc and the thickness of the felt ranges from 1-7 mm.
- the collagen may be in the form of a sponge, a braid or woven threads, etc.
- a convenient nylon mesh is Nitex, a nylon filtration mesh having an average pore size of 210 ⁇ m and an average nylon fiber diameter of 90 ⁇ m (#3-210/36 Tetko, Inc. , N.Y.) .
- the three-dimensional framework provides a greater surface area for protein attachment, and consequently, for the adherence of stromal cells in vivo.
- the stromal cells that attach to the framework continue to actively grow and produce growth and regulatory factors which promote new cartilage formation in vivo, and are less likely to exhibit contact inhibition.
- the three-dimensional framework allows for a spatial distribution of cellular elements which is analogous to that found in vivo.
- the increase in potential volume for cell growth in the three-dimensional structure may allow the establishment of localized microenvironments conducive to cellular differentiation and maturation in the production of new cartilage in vivo.
- the three-dimensional matrix maximizes cell-cell interactions by allowing greater potential for movement of migratory cells, such as macrophages, monocytes and possibly lymphocytes.
- the scaffold may comprise or be modified, e.g. , coated or impregnated, prior to implantation with certain substances to enhance the attachment and growth of chondrocytes and other stromal cells on the scaffold in vivo.
- bioactive agents such cellular growth factors (e.g., TGF- / 3) , substances that stimulate chondrogenesis (e.g., BMPs that stimulate cartilage formation such as BMP-2, BMP-12 and BMP-13) , factors that stimulate migration of stromal cells to the scaffold, factors that stimulate matrix deposition, anti-inflammatories (e.g., non-steroidal anti-inflammatories) , immunosuppressants (e.g., cyclosporins) , as well as other proteins, such as collagens, elastic fibers, reticular fibers, glycoproteins or glycosaminoglycans, such as heparin sulfate, chondroitin-4- sulfate, chondroitin-6-sulfate, dermatan sulfate, keratin sulfate, etc.
- bioactive agents such as cellular growth factors (e.g., TGF- / 3)
- substances that stimulate chondrogenesis e.g.
- chondrocyte differentiation and cartilage formation by chondrocytes have been found to trigger chondrocyte differentiation and cartilage formation by chondrocytes.
- hyaluronic acid is a good substrate for the attachment of chondrocytes and other stromal cells and can be incorporated as part of the scaffold or coated onto the scaffold.
- bioactive agents may also be included in or on the scaffold for local, sustained release of the agents.
- sustained release formulations include composites comprising the bioactive agent and a biocompatible polymer, such as poly(lactic acid), poly(lactic-co-glycolic acid) , methylcellulose, hyaluronic acid, collagen, and the like.
- a biocompatible polymer such as poly(lactic acid), poly(lactic-co-glycolic acid) , methylcellulose, hyaluronic acid, collagen, and the like.
- degradable polymers in drug delivery vehicles have been reviewed in several publications, including, A. Domb et al.. 1992, Polymers for Advanced Technologies 3:279-292. Additional guidance in selecting and using polymers in pharmaceutical formulations can be found in the text by M. Chasin and R.
- the scaffold of the invention as described above is implanted into the defect site in vivo in combination with periosteal tissue, perichondrial tissue or a combination of the two tissues.
- Periosteal tissue is derived from the periosteum, a fibrous membrane localized at the surfaces of bones, and can be obtained from the periosteum/bone interface of any suitable bone of the patient (or subject) or a histoco patible donor, e.g., ileum, scapula, tibia, fibula, femur, etc.
- the periosteal tissue contains a variety of stromal cells including osteocytes, chondrocytes and fibroblasts as well as mesenchymal stem cells having the potential to differentiate into osteogenic or chondrogenic cells.
- Perichondrial tissue is derived from the perichondrium, the fibrous connective tissue covering cartilage, except articular surfaces.
- Perichondrial tissue contains chondrogenic progenitor cells and chondrocytes.
- the periosteal/perichondrial tissue can be in the form of a segment or layer of tissue of any size or shape, preferably of a size and shape that fits within or corresponds to the defect site.
- the tissue can be laid over or under the scaffold at the implantation site and can optionally be mechanically fixed to the scaffold and/or the defect site, e.g., by sutures or glue fixation, e.g., fibrin glue.
- the periosteal/perichondrial tissue may be autologous (i.e., derived from the subject receiving the implant)
- the tissue may be derived from a heterologous source.
- the three-dimensional scaffold is implanted at the defect site in vivo and a piece of periosteal/perichondrial tissue is placed over the implanted scaffold and sutured in place so that the tissue overlays and lies adjacent to the scaffold structure.
- a segment of periosteum or perichondrium may be implanted directly into the defect site and the scaffold placed on top of the tissue such that the stromal cells of the tissue can migrate from the tissue into the scaffold.
- the periosteal/perichondrial tissue should be situated with respect to the scaffold in such a way as to allow the stromal cells from the tissue to migrate into the scaffold and proliferate thereon and therein.
- the scaffold and/or periosteal/perichondrial tissue can be implanted using surgical techniques well known in the art, e.g., arthroscopy.
- the periosteal tissue is situated or oriented such that the cambium layer of the tissue is facing into the defect; thus, in the embodiment wherein the scaffold is placed directly into the defect site and the periosteal tissue is placed on top of the scaffold, the periosteal tissue is oriented in relation to the top of the scaffold such that the cambium layer is facing the top of the scaffold.
- the perichondrial tissue is also placed into the defect site or oriented with respect to the scaffold such that its cambium or inner transition layers faces the defect or scaffold. It is these layers that contain chondrogenic stem cells and/or chondrocytes that can migrate into the scaffold for the production of new cartilage at the defect site.
- a bioresorbable patch e.g., film, mesh or felt
- a bioresorbable patch can be used in place of the periosteal/perichondrial tissue and situated or oriented adjacent to the scaffold within the defect site.
- a film e.g., it may be comprised of PGA or polygluconate; if a mesh or felt is used, they may be comprised of vicryl or PLA.
- the preparation of stromal cells is seeded into the defect site as described herein.
- the defect site is treated, preferably prior to implantation, to degrade the cartilage at the site of the defect, freeing cells (e.g., stromal cells) from that area to migrate into the scaffold of the implant and promoting the orderly deposition of new cartilage.
- freeing cells e.g., stromal cells
- enzymes include but are not limited to trypsin, chymotrypsin, collagenase, elastase, and/or hyaluronidase, Dnase, pronase, chondroitinase, etc.
- Alternative methods of treating the defect site to degrade the cartilage include abrasion, debridement, shaving or icrodrilling.
- the surface of the cartilage may be serrated, e.g., via wire wool.
- a drilling device is used to create small defects or channels in the cartilage. Treatment of the defect site to degrade or disrupt the pre-existing cartilage reduces the chances of scar tissue forming at the site and promotes the orderly deposition of new cartilage at the defect site.
- a preparation of stromal cells is additionally administered at the implantation site, which cells produce biological factors that promote chondrogenesis and the migration of cells such as chondrogenic stem cells or chondrocytes, from the in vivo environment adjacent to the implant, including from the periosteal/perichondrial tissue, to the scaffold for attachment and/or differentiation thereon and therein.
- the stromal cell preparation also provides a direct source of stromal cells, e.g. , chondrocytes and/or chondrocyte progenitor cells, that are capable of migrating to the scaffold, attaching thereto, and elaborating cartilage- specific macromolecules and extracellular matrix proteins for the production of new cartilage at the defect site.
- the cells described herein can be administered before, during or after implantation of the scaffold and/or periosteal/ perichondrial tissue, as discussed in Section 4.4, infra.
- the stromal cells of the preparation may include chondrocytes, chondrocyte progenitor cells including mesenchymal stem cells, fibroblasts, fibroblast-like cells and/or cells capable of producing collagen type II and other collagen types, and proteoglycans which are typically produced in cartilaginous tissues.
- the stromal cells can be obtained from the patient (or subject) or a histocompatible donor.
- chondrocytes, progenitor cells, fibroblast-like cells and other cells and/or elements that comprise the stroma may be fetal or adult in origin, and may be derived from convenient sources such as cartilage, bone, skin, ligaments, tendons, muscles, placenta, umbilical cord, etc.
- stromal cells such as chondrocytes may be derived from any type of cartilage, including but not limited to, hyaline cartilage, costal cartilage, fibrous cartilage, etc. , which can be obtained by biopsy (where appropriate) or upon autopsy.
- Chondrocyte progenitor cells may be derived from various sources including bone marrow, periosteum, perichondrium or various sources of undifferentiated human mesenchyme. Fibroblasts can be obtained in quantity rather conveniently from foreskin, preferably fetal foreskin, or, alternatively, any appropriate cadaver organ. Fetal cells, including fibroblast-like cells and chondrocyte progenitor cells, may be obtained from umbilical cord or placenta tissue or umbilical cord blood.
- stromal cells from a variety of sources may be used in the claimed methods, it is preferable that, for implantation in vivo, the stromal cells be derived from the individual who is to receive the implant or from cells of fetal origin which may be viewed as "universal donors" so as to minimize the risk of immunological rejection of the implant.
- the stromal cells may be readily isolated by disaggregating an appropriate tissue which is to serve as the source of the cells. This may be readily accomplished using techniques known to those skilled in the art.
- the tissue can be disaggregated mechanically and/or treated with digestive enzymes and/or chelating agents that weaken the connections between neighboring cells making it possible to disperse the tissue into a suspension of individual cells without appreciable cell breakage.
- Enzymatic dissociation can be accomplished by mincing the tissue and treating the minced tissue with any of a number of digestive enzymes either alone or in combination.
- the suspension can be fractionated into subpopulations from which chondrocytes, fibroblasts and/or other stromal cells and/or elements can be obtained.
- This also may be accomplished using standard techniques for cell separation including but not limited to cloning and selection of specific cell types, selective destruction of unwanted cells (negative selection) , separation based upon differential cell agglutinability in the mixed population, freeze-thaw procedures, differential adherence properties of the cells in the mixed population, filtration, conventional and zonal centrifugation, centrifugal elutriation (counter- streaming centrifugation) , unit gravity separation, counter current distribution, electrophoresis and fluorescence- activated cell sorting.
- clonal selection and cell separation techniques see Freshney, supra, Ch. 11 and 12, pp. 137-168.
- chondrocytes For example, the isolation of chondrocytes, chondrocyte progenitors, fibroblasts or fibroblast-like cells is carried out as follows: fresh human cartilage tissue can be thoroughly washed and minced in Hanks balanced salt solution (HBSS) in order to remove serum. The minced tissue is incubated from 1-12 hours in a freshly prepared solution of a dissociating enzyme such as trypsin. After such incubation, the dissociated cells are suspended, pelleted by centrifugation and plated onto culture dishes. All fibroblasts will attach before other cells, therefore, appropriate stromal cells can be selectively isolated and grown.
- HBSS Hanks balanced salt solution
- the isolated stromal cells can then be grown to confluency, lifted from the confluent culture and administered to the cartilage defect site in vivo (see, e.g., Naughton et al.. 1987, J. Med. 18(3&4) :219-250) .
- Fibroblast- like cells may also be isolated from human umbilical cords (33-44 weeks) .
- Fresh tissues may be minced into pieces and washed with medium or snap-frozen in liquid nitrogen until further use.
- the umbilical tissues may be disaggregated as described above.
- chondrocytes or chondrocyte progenitor cells have been isolated, their population can be expanded mitotically in vitro in order to obtain the cell preparation for implantation.
- Methods for the selection of the most appropriate culture medium, medium preparation, and cell culture techniques are well known in the art and are described in a variety of sources, including Doyle et al.. (eds.), 1995, Cell & Tissue Culture: Laboratory Procedures. John Wiley & Sons, Chichester; and Ho and Wang (eds.), 1991, Animal Cell Bioreactors. Butterworth-Heinemann, Boston.
- the cells should be transferred or "passaged" to fresh medium when they reach an appropriate density, such as 3 to 6.5 x 10 /cm 2 , or, for example, when they reach a defined percentage of confluency on the surface of a culture dish.
- an appropriate density such as 3 to 6.5 x 10 /cm 2
- the stromal cells may stick to the walls of the culture vessel where they can continue to proliferate and form a confluent monolayer. This should be prevented or minimized, for example, by transferring a portion of the cells to a new culture vessel having fresh medium, since the presence of a confluent monolayer in the culture vessel will tend to "shut down" the growth of cells in the culture.
- Removal of the confluent monolayer or transfer of a portion of the cells to fresh media in a new vessel will usually restore proliferative activity of the cells. Such removal or transfer should be done in any culture vessel which has a monolayer exceeding about 25% confluency.
- the liquid culture can be agitated, for example, on an orbital shaker or in roller bottles, to prevent or minimize the cells from sticking to the vessel walls.
- stromal cells may be maintained or stored in cell "banks" comprising either continuous in vitro cultures of cells requiring regular transfer, or, preferably, cells which have been cryopreserved. Cryopreservation of the cells may be carried out according to known methods, such as those described in Doyle et al.. 1995, supra.
- cells may be suspended in a "freeze medium” such as, for example, culture medium further comprising 20% FBS and 9% dimethylsulfoxide (DMSO) , with or without 5-10% glycerol, at a density, for example, of about 4-10 x 10 6 cells/ml.
- DMSO dimethylsulfoxide
- the cells are dispensed into glass or plastic ampoules (Nunc) which are then sealed and transferred to the freezing chamber of a programmable freezer.
- the optimal rate of freezing may be determined empirically. For example, a freezing program that gives a change in temperature of -l°C/min through the heat of fusion may be used.
- a freezing program that gives a change in temperature of -l°C/min through the heat of fusion may be used.
- Once the ampoules have reached -180°C they are transferred to a liquid nitrogen storage area. Cryopreserved cells can be stored for a period of years, though they should be checked at least every 5 years for maintenance of viability.
- the cryopreserved cells constitute a bank of cells, portions of which can be "withdrawn” by thawing and then used to produce new cartilage tissue as needed.
- Thawing should generally be carried out rapidly, for example, by transferring an ampoule from liquid nitrogen to a 37°C water bath.
- the thawed contents of the ampoule should be immediately transferred under sterile conditions to a culture vessel containing an appropriate medium such as RPMI 1640 conditioned with 10% FBS and 5% ES.
- an appropriate medium such as RPMI 1640 conditioned with 10% FBS and 5% ES. It is advisable that the cells in the culture medium be adjusted to an initial density of about 3-6 x 10 5 cells/ml so that the cells can condition the medium as soon as possible, thereby preventing a protracted lag phase.
- the cells may be examined daily, for example, with an inverted microscope to detect cell proliferation, and subcultured as soon as they reach an appropriate density.
- chondrocytes In addition to chondrocytes, chondrocyte progenitors, fibroblasts or fibroblast-like cells, other cells may be added to the cell preparation for implantation in vivo, which other cells aid in the production of the stromal matrix on the scaffold of the invention.
- other cells found in loose connective tissue may be seeded along with chondrocytes or fibroblasts.
- Such cells include but are not limited to endothelial cells, pericytes, macrophages, monocytes, plasma cells, mast cells, adipocytes, etc.
- These stromal cells may readily be derived from appropriate organs including umbilical cord or placenta or umbilical cord blood using methods known in the art such as those discussed above.
- the stromal cell preparation may further comprise one or more other components, including selected extracellular matrix components, such as one or more types of collagen known in the art, as well as growth factors and/or drugs.
- Growth factors which may be usefully incorporated into the cell preparation include one or more tissue growth or stimulatory factors known in the art or to be identified in the future, including but not limited to any member of the TGF-3 family, BMPs that stimulate cartilage formation, e.g., BMP-2, BMP-12, and BMP-13, factors that stimulate migration of stromal cells and/or matrix deposition, insulin-like growth factor (IGF)-I and -II, growth hormone, etc.
- IGF insulin-like growth factor
- Drugs which may be usefully incorporated into the cell preparation include anti-inflammatory compounds such as non-steroidal anti-inflammatories, immunosuppressants such as the cyclosporins, as well as local anesthetics.
- Other components may also be included in the preparation, including but not limited to any of the following: (1) buffers to provide appropriate pH and isotonicity; (2) lubricants; (3) viscous materials to retain the cells at or near the site of administration, including, for example, alginates, agars and plant gums; and (4) other cell types that may produce a desired effect at the site of administration, such as, for example, enhancement or modification of the formation of cartilage tissue or its physicochemical characteristics, or support for the viability of the cells, or inhibition of inflammation or rejection.
- the stromal cells may be obtained from the patient's own tissues or from a fetal source ("universal donor") .
- the growth of cells on the three-dimensional scaffold may be further enhanced by including in or on the framework or coating the framework with proteins (e.g., collagens, elastic fibers, reticular fibers) , glycoproteins, glycosaminoglycans (e.g., heparin sulfate, chondroitin-4- sulfate, chondroitin-6-sulfate, dermatan sulfate, keratin sulfate, etc.), and/or other bioactive materials such as growth factors.
- proteins e.g., collagens, elastic fibers, reticular fibers
- glycoproteins e.g., glycoproteins, glycosaminoglycans (e.g., heparin sulfate, chondroitin-4- sulfate, chondroitin-6-sulfate, dermatan
- growth regulatory or stimulatory factors including, but not limited to, TGF-/S and ascorbate, or BMPs that stimulate cartilage formation such as BMP-2, BMP-12, and BMP-13 may be added to the implantation site before, during or after implantation of either the scaffold and/or the periosteal/perichondrial tissue, in order to promote the production of new cartilage at the site.
- growth regulatory factors can be administered to the site at the time of administration of the stromal cells, either as a separate preparation or, as noted supra. as part of the stromal cell preparation.
- the stromal cells may be genetically engineered to produce growth factors such as TGF- / S as well as other biological factors such as factors that stimulate chondrogenesis or the migration of chondrogenic and other stromal cells to the scaffold of this invention.
- the stromal cells administered to or in combination with the scaffold and periosteal/perichondrial tissue of the invention can also be genetically engineered to produce gene products that promote the successful production or repair of cartilage at a defect site and/or for use in gene therapies.
- the stromal cells can be genetically engineered to express anti-inflammatory factors, e.g., anti-GM-CSF, anti-TNF, anti-IL-1, anti-IL-2, etc., to reduce the risk of rejection of the implant or to reduce the risk of degenerative changes in the cartilage due to rheumatoid disease or other inflammatory reactions.
- the stromal cells can be genetically engineered to express peptides or polypeptides corresponding to the idiotype of neutralizing antibodies for granulocyte-macrophage colony stimulating factor (GM-CSF), TNF, IL-1, IL-2, or other inflammatory cytokines.
- GM-CSF granulocyte-macrophage colony stimulating factor
- TNF granulocyte-macrophage colony stimulating factor
- IL-1 has been shown to decrease the synthesis of proteoglycans and collagens type II, IX, and XI (Tyler et al. , 1985, Biochem. J. 227:869-878; Tyler et al.. 1988, Coll. Relat. Res. 82: 393-405; Goldring et al.. 1988, J. Clin. Invest.
- TNF also inhibits synthesis of proteoglycans and type II collagen, although it is much less potent than IL-1 (Yaron, I., et al.. 1989, Arthritis Rheum. 32:173-180; Ikebe, T. , et al.. 1988, J. Immunol. 140:827-831; and Saklatvala, J. , 1986, Nature 322:547-549).
- the presence of the anti- inflammatory gene products can bring about amelioration of immunological rejection or the inflammatory reactions associated with rheumatoid or joint disease.
- the stromal cells can be genetically engineered to express a gene which would exert a therapeutic effect, e.g., in the production of TGF- ⁇ to stimulate cartilage production, or other factors such as BMP- 13 to promote chondrogenesis and/or prevent bone formation or stimulatory factors that promote migration of stromal cells and/or matrix deposition.
- the stromal cells can be genetically engineered to express a gene for which a patent is deficient.
- genes that prevent or ameliorate symptoms of various types of rheumatoid or joint diseases may be underexpressed or down-regulated under disease conditions. Specifically, expression of genes involved in preventing inflammatory reactions in rheumatoid or joint diseases may be down-regulated.
- the activity of gene products may be diminished, leading to the manifestations of some or all of the above pathological conditions and eventual development of symptoms of rheumatoid or joint diseases.
- the level of gene activity may be increased by either increasing the level of gene product present or by increasing the level of the active gene product present at the defect site.
- Target gene refers to a gene involved in rheumatoid or joint diseases in a manner by which modulation of the level of target gene expression or of target gene product activity may act to ameliorate symptoms of rheumatoid or joint diseases by preventing resorption of cartilage and production of inflammatory mediators by chondrocytes.
- patients may be treated by gene replacement therapy by means of the stromal cells administered according to the methods of this invention.
- replacement or repaired cartilage may be designed specifically to meet the requirements of an individual patient; for example, the stromal cells may be genetically engineered to regulate one or more genes; or the regulation of gene expression may be transient or long-term; or the gene activity may be non- inducible or inducible.
- the gene encoding the human complement regulatory protein, which prevents rejection of an implant by the host may be inserted into human fibroblasts. McCurry et al.. 1995, Nature Medicine 1:423- 427.
- the stromal cells used in the methods of the invention can also be genetically engineered to "knock out” expression of factors that promote inflammation or rejection at the implant site. Negative modulatory techniques for the reduction of target gene expression levels or target gene product activity levels are discussed below. "Negative modulation”, as used herein, refers to a reduction in the level and/or activity of target gene product relative to the level and/or activity of the target gene product in the absence of the modulatory treatment.
- the expression of a gene native to stromal cell can be reduced or knocked out using a number of techniques, for example, expression may be inhibited by inactivating the gene completely (commonly termed "knockout") using standard homologous recombination techniques.
- an exon encoding an important region of the protein is interrupted by a positive selectable marker (for example neo) , preventing the production of normal mRNA from the target gene and resulting in inactivation of the gene.
- a gene may also be inactivated by creating a deletion in part of a gene, or by deleting the entire gene. By using a construct with two regions of homology to the target gene that are far apart in the genome, the sequences intervening the two regions can be deleted. Mombaerts et al.. 1991, Proc. Nat. Acad. Sci. U.S.A. 88:3084-3087.
- Antisense and ribozyme molecules which inhibit expression of the target gene can also be used in accordance with the invention to reduce the level of target gene activity.
- antisense RNA molecules which inhibit the expression of major histocompatibility gene complexes (HLA) have been shown to be most versatile with respect to immune responses.
- appropriate ribozyme molecules can be designed as described, e.g. , by Haseloff et al. , 1988, Nature 334:585-591; Zaug et al.. 1984, Science 224:574-578; and Zaug and Cech, 1986, Science 231:470-475.
- triple helix molecules can be utilized in reducing the level of target gene activity.
- the expression of IL-1 can be knocked out in the chondrocytes to reduce the risk of resorption of cartilage and production of inflammatory mediators by the chondrocytes.
- the expression of MHC class II molecules can be knocked out in order to reduce the risk of rejection of the implant.
- a recombinant DNA construct or vector containing the gene of interest may be constructed and used to transform or transfect the stromal cells of the invention.
- Such transformed or transfected cells that carry the gene of interest, and that are capable of expressing said gene are selected and clonally expanded in culture.
- Methods for preparing DNA constructs containing the gene of interest, for transforming or transfecting cells, and for selecting cells carrying and expressing the gene of interest are well-known in the art. See, for example, the techniques described in Maniatis et al. , 1989, Molecular Cloning.
- the cells can be engineered using any of a variety of vectors including, but not limited to, integrating viral vectors, e.g. , retrovirus vector or adeno-associated viral vectors; or non-integrating replicating vectors, e.g., papillo a virus vectors, SV40 vectors, adenoviral vectors; or replication-defective viral vectors.
- integrating viral vectors e.g. , retrovirus vector or adeno-associated viral vectors
- non-integrating replicating vectors e.g., papillo a virus vectors, SV40 vectors, adenoviral vectors
- replication-defective viral vectors e.g., papillo a virus vectors, SV40 vectors, adenoviral vectors
- replication-defective viral vectors e.g., papillo a virus vectors, SV40 vectors, adenoviral vectors
- replication-defective viral vectors e.
- Hosts cells are preferably transformed or transfected with DNA controlled by, i.e., in operative association with, one or more appropriate expression control elements such as promoter or enhancer sequences, transcription terminators, polyadenylation sites, among others, and a selectable marker.
- engineered cells may be allowed to grow in enriched media and then switched to selective media.
- the selectable marker in the foreign DNA confers resistance to the selection and allows cells to stably integrate the foreign DNA as, for example, on a plasmid, into their chromosomes and grow to form foci which, in turn, can be cloned and expanded into cell lines. This method can be advantageously used to engineer cell lines which express the gene product.
- any promoter may be used to drive the expression of the inserted gene.
- viral promoters include but are not limited to the CMV promoter/enhancer, SV40, papillo avirus, Epstein-Barr virus, elastin gene promoter and ⁇ -globin.
- the control elements used to control expression of the gene of interest should allow for the regulated expression of the gene so that the product is synthesized only when needed in vivo.
- constitutive promoters are preferably used in a non-integrating and/or replication-defective vector.
- inducible promoters could be used to drive the expression of the inserted gene when necessary.
- Inducible promoters can be built into integrating and/or replicating vectors.
- inducible promoters include, but are not limited to, metallothionien and heat shock protein.
- transkaryotic as used herein, suggests that the nuclei of the implanted cells have been altered by the addition of DNA sequences by stable or transient transfection.
- the stromal cells are engineered to express such gene products transiently and/or under inducible control during the post ⁇ operative recovery period, or as a chimeric fusion protein anchored to the stromal cells, for example, as a chimeric molecule composed of an intracellular and/or transmembrane domain of a receptor or receptor-like molecule, fused to the gene product as the extracellular domain.
- a chimeric fusion protein anchored to the stromal cells for example, as a chimeric molecule composed of an intracellular and/or transmembrane domain of a receptor or receptor-like molecule, fused to the gene product as the extracellular domain.
- the preparation of stromal cells can be administered either before, during or after implantation of the scaffold and/or the periosteal/perichondrial tissue.
- the cells can be seeded into the defect site before implantation of either the scaffold or the periosteal/perichondrial tissue.
- the stromal cells can be administered to the site after either one or both of the scaffold and tissue have been implanted; e.g. , by injection into the site after suturing the periosteal/perichondrial tissue to the scaffold.
- the cells are seeded between the periosteal/perichondrial tissue and the scaffold at the defect site.
- the cells are seeded directly into the scaffold.
- the stromal cells can also be seeded into the degraded cartilage, e.g., into the surrounding cells or directly into the cartilage wall.
- the stromal cells act therein to induce the migration of stromal cells from the degraded cartilage to the implant.
- the stromal cells can be seeded by any means that allows administration of the cells to the defect site, e.g., by injection.
- administration of the cells e.g., by injection.
- such injection can be achieved by any means that maintains the viability of the cells, e.g., via syringe or more preferably, via an arthroscope.
- the number of cells administered can range from approximately 1 x IO 6 to 30 x 10 6 stromal cells.
- the defect site is surgically sealed.
- the stromal cells to be seeded are surgically obtained from the patient, e.g., from ear cartilage and/or bone marrow, in a separate surgical procedure, cultured in vitro to obtain an appropriate amount of cells and administered to the patient at the time of a second surgery wherein the scaffold and periosteal/perichondrial tissue are implanted.
- the periosteal/perichondrial tissue is preferably surgically obtained from the patient at the time that the scaffold is implanted, although the tissue can be cultured ij vitro prior to implantation (see, e.g., O'Driscoll et al. , 1994, J. Bone and Joint Surg. 76-A:1042-1051) .
- the stromal cells from the periosteal/perichondrial tissue and from the added stromal preparation populate the scaffold structure to form a stromal matrix that resembles the in vivo microenvironment of cartilage tissue, allowing for the production of new cartilage at the defect site.
- the stromal cells administered to the site provide important biological factors that promote chondrogenesis and the migration of stromal cells, whether from the implanted tissue, the in vivo cartilage environment of the defect or from the stromal preparation, to the scaffold, thus promoting the production of a living stromal tissue that provides the support, growth factors, and regulatory factors necessary to sustain long- term active proliferation of the stromal cells in vivo.
- the stromal cells may additionally provide factors that promote the deposition of the living stromal matrix at the defect site. The proliferating cells mature and segregate properly within the matrix to form new cartilage tissue at the defect site in vivo.
- the successful repair or replacement of damaged cartilage can be enhanced if the new cartilage tissue can be fixed in place at the site of repair. Post-implantation movement may cause the new cartilage tissue to become dislodged from the site if a pro-active fixation technique is not employed.
- Various methods can be used to fix the new cartilage tissue in place, including: patches derived from a bioresorbable polymer or biocompatible tissues, which can be placed over the site and sutured; bioabsorbable sutures or other fasteners, e.g., pins, staples, tacks, screws, anchors, glues, e.g., fibrin glue; non-absorbable fixation devices, e.g., sutures, pins, screws and anchors; adhesives; and the use of interference fit geometries.
- the methods of this invention are useful to replace or augment existing cartilage tissue in vivo, to introduce new or altered cartilage tissue or to join together biological tissues or structures.
- the present methods find use in a number of specific areas.
- the evaluation of internal derangements of articular cartilage in several articulations, including the knee, hip, elbow, ankle and the glenohumeral joint has been made possible by arthroscopic techniques.
- Such derangements can be caused by physical trauma to the cartilage, by various connective tissues diseases and/or by increased age of the individual.
- Arthroscopic surgery has become increasingly popular as well as successful, e.g., numerous small cutting tools, 3 to 4mm in diameter can be used in the knee.
- Triangulation in which the operating instruments are brought into the visual field provided by the arthroscope, requires multiple portals of entry; alternatively, the cutting tools can be passed through a channel in the arthroscope itself in which case only one opening in the joint is necessary (Jackson, R.W. , 1983, J. Bone Joint Surg. [AM] 65:416) .
- Selective removal of damaged or deteriorated cartilage via arthroscopic surgery results in cartilage loss, which can be repaired using the methods of the present invention.
- the present methods can also be employed to repair or augment cartilage loss that results from major reconstructive surgery for different types of joints, the procedures for which surgery have been described in Resnick, D. , and Niwayama, G.
- the present invention is useful for the production or repair of cartilage in vivo in the treatment of degenerative connective tissue diseases, such as rheumatoid or osteoarthritis, or in the treatment of physical trauma, wherein cartilage is damaged or lost.
- a three-dimensional scaffold comprising felt derived from a PGA multifilament yarn was generated.
- the yarn is commercially available from Davis and Geek/Sherwood Medical under the trade name DexonTM.
- the particular type of DexonTM yarn is 56/123.
- the DexonTM yarn is processed into felt via standard textile processing techniques.
- the felt sheet which has a porosity of 97%, a density of 45 g/cc and a thickness of 2-7 mm after processing, is cut into the appropriate size for implantation in vivo. Standard serialization techniques (radiation or ethylene oxide gas) for medical products are used to sterilize the felt.
- the felt can be implanted dry or pre-soaked using DMEM medium containing 10% fetal bovine serum, 2 mM L-glutamine, non- essential amino acids, 50 mg/ml proline, 1 mM sodium pyruvate, 35 ⁇ g/ml gentamicin sulfate and 50 ⁇ g/ml ascorbate. 5.2. PREPARATION OF PERIOSTEAL/ PERICHONDRIAL TISSUE
- Periosteal tissue to be used in the methods of this invention is obtained by removing, e.g. , by arthroscopy, a section of periosteum from the tibia or femur of the patient.
- Perichondrial tissue can be obtained by removing a section of the perichondrium from the rib of the patient.
- the periosteal/perichondrial tissue is of such size and/or shape so as to correspond to the defect site.
- the excision of the periosteal/perichondrial tissue from the patient is preferably performed at the time of the implantation of the scaffold.
- cartilage slices e.g., 300- 500 mg by weight
- cartilage slices can be obtained by arthroscopy from a minor load-bearing area of a joint such as the femoral condyle of the knee.
- the cartilage tissue is placed in a chilled sterile solution of sodium chloride (0.9 % weight per volume) and cells are harvested within 2-5 hr by mincing and washing in Ham's F12 medium (Gibco Labs, Grand Island, NY) containing HEPES buffer (10 mmol/1) , gentamicin sulfate (50 ⁇ g/ml) , amphotericin B (2 ⁇ g/ml) , and L-ascorbic acid (50 ⁇ g/ml) .
- the cells can similarly be harvested using the complete DMEM medium described in Section 5.1, supra.
- the cartilage is then digested with collagenase (0.2% weight/volume) for approximately 16 hr and the cells are filtered through a nylon mesh, washed with medium and resuspended in medium supplemented with the patient's serum.
- the cells are seeded at a density of approximately 1 X 10 6 cells per T-150 flask and cultured in an incubator at 37°C, 5% C0 2 . Cells are passed at confluence every 5-7 days.
- chondrocyte progenitor cells can be obtained using methods similar to those described in Wakitani et al.. 1994, J. Bone and Joint Surg. 76-A (No.
- the cells are then trypsinized (0.25% trypsin, 1 mM EDTA) for 5 min, to release the cells from the culture dish.
- Chondrocyte progenitor cells can also be obtained from periosteum harvested, e.g., from the tibia or femur. The periosteal tissue is incubated with 0.25% collagenase in
- the stromal cell preparation Prior to administration in vivo, the stromal cell preparation is suspended by treatment with trypsin, centrifuged and the pellet washed in culture medium
- the cell preparation is then aspirated into a 1 ml tuberculin syringe with a 1.2 mm needle for administration to the implant site.
- the cartilage defect site is cleaned/sterilized prior to implantation by scrubbing or rinsing with a sterilizing solution, e.g., iodine surgical scrub, e.g., 0.75% titratable iodine, or 0.9% sodium chloride solution.
- a sterilizing solution e.g., iodine surgical scrub, e.g., 0.75% titratable iodine, or 0.9% sodium chloride solution.
- __ can also be enzymatically treated to degrade the cartilage surface area of the defect by treatment with trypsin in the range of 0.1-100 Units/ml for 1-30 min depending upon the concentration of enzyme used.
- the felt scaffold as described above, tailored to fit the defect site, is placed into the site and the periosteal tissue as described above is placed on top of the felt scaffold with the cambium layer of the periosteum facing toward the scaffold and into the defect.
- the periosteal tissue may optionally be sewn onto the ends of the felt scaffold using resorbable vicryl sutures.
- the flap is also sutured to the surrounding cartilage at the defect site.
- the stromal cells of the preparation described above can be administered, e.g., by an arthroscope, into the defect site.
- an arthroscope For a defect 5 mm thick and 1.5 cm in diameter, a total of 14 x 10 6 stromal cells in 200 ⁇ l of a nutrient-based solution such as DMEM (with or without serum) is administered.
- the stromal cells are injected between the periosteal tissue and the scaffold.
- the defect site is closed in layers with sutures and the site bandaged.
- a post-surgical analgesic may be administered.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ331517A NZ331517A (en) | 1996-02-21 | 1997-02-20 | A method for making and/or repairing cartilage in vivo by implanting a scaffold or framework in combination with periosteal/perichondrial tissue that holds the scaffold in place |
JP9530388A JP2000505338A (en) | 1996-02-21 | 1997-02-20 | Method of forming and / or repairing cartilage |
EP97907835A EP0955959A1 (en) | 1996-02-21 | 1997-02-20 | Method for making and/or repairing cartilage |
AU19731/97A AU715282B2 (en) | 1996-02-21 | 1997-02-20 | Method for making and/or repairing cartilage |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/604,284 | 1996-02-21 | ||
US08/604,284 US5842477A (en) | 1996-02-21 | 1996-02-21 | Method for repairing cartilage |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997030662A1 true WO1997030662A1 (en) | 1997-08-28 |
Family
ID=24418997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/002909 WO1997030662A1 (en) | 1996-02-21 | 1997-02-20 | Method for making and/or repairing cartilage |
Country Status (8)
Country | Link |
---|---|
US (1) | US5842477A (en) |
EP (1) | EP0955959A1 (en) |
JP (1) | JP2000505338A (en) |
KR (1) | KR19990087147A (en) |
AU (1) | AU715282B2 (en) |
CA (1) | CA2247158A1 (en) |
NZ (1) | NZ331517A (en) |
WO (1) | WO1997030662A1 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998042389A1 (en) * | 1997-03-25 | 1998-10-01 | Peter Villeneuve | Materials for healing cartilage and bone defects |
WO1999011789A1 (en) * | 1997-09-04 | 1999-03-11 | North Shore University Hospital Research Corporation | Genetic engineering of cells to enhance healing and tissue regeneration |
WO1999025396A2 (en) * | 1997-11-17 | 1999-05-27 | The Regents Of The University Of Michigan | Hybrid tissues for tissue engineering |
WO2000009179A2 (en) * | 1998-08-14 | 2000-02-24 | Verigen Transplantation Service International (Vtsi) Ag | Methods, instruments and materials for chondrocyte cell transplantation |
US6283980B1 (en) | 1996-08-30 | 2001-09-04 | Verigen Transplantation Services Internt'l | Method, instruments, and kit for autologous transplantation |
WO2002010348A2 (en) * | 2000-07-29 | 2002-02-07 | Smith & Nephew Plc | Tissue implant for cartilage repair |
US6569172B2 (en) | 1996-08-30 | 2003-05-27 | Verigen Transplantation Service International (Vtsi) | Method, instruments, and kit for autologous transplantation |
EP1416888A2 (en) * | 2001-07-16 | 2004-05-12 | Depuy Products, Inc. | Meniscus regeneration device and method |
EP1416879A2 (en) * | 2001-07-16 | 2004-05-12 | Depuy Products, Inc. | Unitary surgical device and method |
EP1656960A1 (en) * | 1998-08-14 | 2006-05-17 | Verigen AG | Methods, instruments and materials for chondrocyte cell transplantation |
US7445793B2 (en) | 2002-09-09 | 2008-11-04 | Kaneka Corporation | Support for tissue regeneration and process for producing the same |
JP2009102393A (en) * | 1997-02-07 | 2009-05-14 | Stryker Corp | Matrix-free osteogenic devices, implants and methods of use thereof |
US20100189712A1 (en) * | 2006-11-17 | 2010-07-29 | Cytograft Tissue Engineering, Inc. | Preparation And Use Of Cell-Synthesized Threads |
EP1276486B1 (en) * | 2000-04-25 | 2010-11-24 | Osiris Therapeutics, Inc. | Joint repair using mesenchymal stem cells |
US7871440B2 (en) | 2006-12-11 | 2011-01-18 | Depuy Products, Inc. | Unitary surgical device and method |
AU2007203472B2 (en) * | 2000-07-29 | 2011-07-14 | Smith & Nephew Plc | Tissue implant for cartilage repair |
US8137689B1 (en) | 1999-11-11 | 2012-03-20 | Zimmer Gmbh | Transplant/implant device and method for its production |
US8173162B2 (en) | 2003-02-26 | 2012-05-08 | Zimmer Orthobiologics, Inc. | Preparation for repairing cartilage tissue, especially articular cartilage defects |
US8691259B2 (en) | 2000-12-21 | 2014-04-08 | Depuy Mitek, Llc | Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
US8895045B2 (en) | 2003-03-07 | 2014-11-25 | Depuy Mitek, Llc | Method of preparation of bioabsorbable porous reinforced tissue implants and implants thereof |
US8945535B2 (en) | 2005-09-20 | 2015-02-03 | Zimmer Orthobiologics, Inc. | Implant for the repair of a cartilage defect and method for manufacturing the implant |
US9211362B2 (en) | 2003-06-30 | 2015-12-15 | Depuy Mitek, Llc | Scaffold for connective tissue repair |
US9238090B1 (en) | 2014-12-24 | 2016-01-19 | Fettech, Llc | Tissue-based compositions |
US9486558B2 (en) | 2003-03-27 | 2016-11-08 | Locate Therapeutics Limited | Porous matrix |
US9511171B2 (en) | 2002-10-18 | 2016-12-06 | Depuy Mitek, Llc | Biocompatible scaffolds with tissue fragments |
US10583220B2 (en) | 2003-08-11 | 2020-03-10 | DePuy Synthes Products, Inc. | Method and apparatus for resurfacing an articular surface |
US11395865B2 (en) | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
Families Citing this family (374)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9503492D0 (en) * | 1995-02-22 | 1995-04-12 | Ed Geistlich S Hne A G F R Che | Chemical product |
US20050186673A1 (en) * | 1995-02-22 | 2005-08-25 | Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie | Collagen carrier of therapeutic genetic material, and method |
US6974571B2 (en) * | 1995-03-28 | 2005-12-13 | Thomas Jefferson University | Isolated stromal cells and methods of using the same |
US6653134B2 (en) * | 1995-03-28 | 2003-11-25 | Cp Hahnemann University | Isolated stromal cells for use in the treatment of diseases of the central nervous system |
EP0920490A2 (en) * | 1996-07-25 | 1999-06-09 | Genzyme Corporation | Chondrocyte media formulations and culture procedures |
US6187053B1 (en) * | 1996-11-16 | 2001-02-13 | Will Minuth | Process for producing a natural implant |
US7468075B2 (en) | 2001-05-25 | 2008-12-23 | Conformis, Inc. | Methods and compositions for articular repair |
US8545569B2 (en) | 2001-05-25 | 2013-10-01 | Conformis, Inc. | Patient selectable knee arthroplasty devices |
US20070100462A1 (en) | 2001-05-25 | 2007-05-03 | Conformis, Inc | Joint Arthroplasty Devices |
US8480754B2 (en) | 2001-05-25 | 2013-07-09 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US10085839B2 (en) | 2004-01-05 | 2018-10-02 | Conformis, Inc. | Patient-specific and patient-engineered orthopedic implants |
US8882847B2 (en) | 2001-05-25 | 2014-11-11 | Conformis, Inc. | Patient selectable knee joint arthroplasty devices |
US8735773B2 (en) | 2007-02-14 | 2014-05-27 | Conformis, Inc. | Implant device and method for manufacture |
US9603711B2 (en) | 2001-05-25 | 2017-03-28 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US7534263B2 (en) | 2001-05-25 | 2009-05-19 | Conformis, Inc. | Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty |
US8771365B2 (en) | 2009-02-25 | 2014-07-08 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs, and related tools |
US8556983B2 (en) | 2001-05-25 | 2013-10-15 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs and related tools |
US7618451B2 (en) | 2001-05-25 | 2009-11-17 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools facilitating increased accuracy, speed and simplicity in performing total and partial joint arthroplasty |
US8083745B2 (en) | 2001-05-25 | 2011-12-27 | Conformis, Inc. | Surgical tools for arthroplasty |
WO1998036705A1 (en) * | 1997-02-20 | 1998-08-27 | Keller Gregory S | Augmentation and repair of dermal, subcutaneous, and vocal cord tissue defects |
US7767452B2 (en) * | 1997-02-20 | 2010-08-03 | Kleinsek Don A | Tissue treatments with adipocyte cells |
US6245537B1 (en) * | 1997-05-12 | 2001-06-12 | Metabolix, Inc. | Removing endotoxin with an oxdizing agent from polyhydroxyalkanoates produced by fermentation |
US6110209A (en) * | 1997-08-07 | 2000-08-29 | Stone; Kevin R. | Method and paste for articular cartilage transplantation |
EP0896825B1 (en) | 1997-08-14 | 2002-07-17 | Sulzer Innotec Ag | Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors |
US20050186283A1 (en) * | 1997-10-10 | 2005-08-25 | Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie | Collagen carrier of therapeutic genetic material, and method |
US7637948B2 (en) | 1997-10-10 | 2009-12-29 | Senorx, Inc. | Tissue marking implant |
US8858981B2 (en) * | 1997-10-10 | 2014-10-14 | Ed. Geistlich Soehne Fuer Chemistrie Industrie | Bone healing material comprising matrix carrying bone-forming cells |
US8668737B2 (en) | 1997-10-10 | 2014-03-11 | Senorx, Inc. | Tissue marking implant |
US20030099620A1 (en) * | 1997-10-30 | 2003-05-29 | The General Hospital Corporation | Bonding of cartilaginous matrices using isolated chondrocytes |
US6183737B1 (en) | 1997-10-30 | 2001-02-06 | The General Hospital Corporation | Bonding of cartilage pieces using isolated chondrocytes and a biological gel |
US5932552A (en) * | 1997-11-26 | 1999-08-03 | Keraplast Technologies Ltd. | Keratin-based hydrogel for biomedical applications and method of production |
US6110487A (en) * | 1997-11-26 | 2000-08-29 | Keraplast Technologies Ltd. | Method of making porous keratin scaffolds and products of same |
WO1999041403A1 (en) * | 1998-02-12 | 1999-08-19 | The Regents Of The University Of California | Compositions for receptor/liposome mediated transfection and methods of using same |
US6224630B1 (en) | 1998-05-29 | 2001-05-01 | Advanced Bio Surfaces, Inc. | Implantable tissue repair device |
US7239908B1 (en) | 1998-09-14 | 2007-07-03 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and devising treatment |
US7184814B2 (en) | 1998-09-14 | 2007-02-27 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and assessing cartilage loss |
AU772012B2 (en) | 1998-09-14 | 2004-04-08 | Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and preventing damage |
US6727224B1 (en) * | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
US7651505B2 (en) | 2002-06-17 | 2010-01-26 | Senorx, Inc. | Plugged tip delivery for marker placement |
US7983734B2 (en) | 2003-05-23 | 2011-07-19 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US8361082B2 (en) | 1999-02-02 | 2013-01-29 | Senorx, Inc. | Marker delivery device with releasable plug |
US9820824B2 (en) | 1999-02-02 | 2017-11-21 | Senorx, Inc. | Deployment of polysaccharide markers for treating a site within a patent |
US8498693B2 (en) | 1999-02-02 | 2013-07-30 | Senorx, Inc. | Intracorporeal marker and marker delivery device |
US20090216118A1 (en) | 2007-07-26 | 2009-08-27 | Senorx, Inc. | Polysaccharide markers |
US6725083B1 (en) | 1999-02-02 | 2004-04-20 | Senorx, Inc. | Tissue site markers for in VIVO imaging |
US6862470B2 (en) | 1999-02-02 | 2005-03-01 | Senorx, Inc. | Cavity-filling biopsy site markers |
DE60036863T2 (en) | 1999-03-25 | 2008-07-31 | Metabolix, Inc., Cambridge | Medical devices and uses of polyhydroxyalkanoate polymers |
US6315992B1 (en) * | 1999-06-30 | 2001-11-13 | Tissuegene Co. | Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1 |
US6575991B1 (en) | 1999-06-17 | 2003-06-10 | Inrad, Inc. | Apparatus for the percutaneous marking of a lesion |
US7338655B1 (en) * | 1999-06-30 | 2008-03-04 | Tissuegene, Inc. | Gene therapy using TGF-β |
US6849594B1 (en) | 1999-06-30 | 2005-02-01 | John Lawler | Purification and use of human recombinant cartilage oligomeric matrix protein |
US20020095157A1 (en) | 1999-07-23 | 2002-07-18 | Bowman Steven M. | Graft fixation device combination |
US6179840B1 (en) | 1999-07-23 | 2001-01-30 | Ethicon, Inc. | Graft fixation device and method |
US7078232B2 (en) * | 1999-08-19 | 2006-07-18 | Artecel, Inc. | Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof |
US6429013B1 (en) * | 1999-08-19 | 2002-08-06 | Artecel Science, Inc. | Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair |
US6783546B2 (en) | 1999-09-13 | 2004-08-31 | Keraplast Technologies, Ltd. | Implantable prosthetic or tissue expanding device |
US7025980B1 (en) * | 1999-09-14 | 2006-04-11 | Tepha, Inc. | Polyhydroxyalkanoate compositions for soft tissue repair, augmentation, and viscosupplementation |
FR2798671A1 (en) * | 1999-09-16 | 2001-03-23 | Univ Paris Curie | CHONDROCYTE COMPOSITIONS, PREPARATION AND USES |
US7951201B2 (en) | 1999-10-20 | 2011-05-31 | Anulex Technologies, Inc. | Method and apparatus for the treatment of the intervertebral disc annulus |
US7615076B2 (en) | 1999-10-20 | 2009-11-10 | Anulex Technologies, Inc. | Method and apparatus for the treatment of the intervertebral disc annulus |
US6592625B2 (en) | 1999-10-20 | 2003-07-15 | Anulex Technologies, Inc. | Spinal disc annulus reconstruction method and spinal disc annulus stent |
US8632590B2 (en) | 1999-10-20 | 2014-01-21 | Anulex Technologies, Inc. | Apparatus and methods for the treatment of the intervertebral disc |
US8128698B2 (en) | 1999-10-20 | 2012-03-06 | Anulex Technologies, Inc. | Method and apparatus for the treatment of the intervertebral disc annulus |
US7004970B2 (en) | 1999-10-20 | 2006-02-28 | Anulex Technologies, Inc. | Methods and devices for spinal disc annulus reconstruction and repair |
US7052516B2 (en) | 1999-10-20 | 2006-05-30 | Anulex Technologies, Inc. | Spinal disc annulus reconstruction method and deformable spinal disc annulus stent |
US7935147B2 (en) | 1999-10-20 | 2011-05-03 | Anulex Technologies, Inc. | Method and apparatus for enhanced delivery of treatment device to the intervertebral disc annulus |
US7799325B2 (en) * | 1999-11-05 | 2010-09-21 | Kleinsek Donald A | Removal of hypertrophic scars |
US20080267923A2 (en) * | 1999-11-05 | 2008-10-30 | Donald Kleinsek | Hair undifferentiated cells |
EP1263931A4 (en) * | 1999-11-05 | 2009-07-15 | Gerigene Medical Corp | Augmentation and repair of age-related soft tissue defects |
US20080286242A2 (en) * | 1999-11-05 | 2008-11-20 | Donald Kleinsek | Augmentation and repair of spincter defects with cells including mesenchymal cells |
US20090074729A2 (en) * | 1999-11-05 | 2009-03-19 | Donald Kleinsek | Augmentation and repair of spincter defects with cells including fibroblasts |
DK1229940T3 (en) | 1999-11-15 | 2014-08-18 | Piramal Healthcare Canada Ltd | TEMPERATURE CONTROL AND PH-DEPENDENT SELF-GELING, Aqueous BIOPOLYMER SOLUTION |
AU1848601A (en) * | 1999-12-09 | 2001-06-18 | Bio Syntech Canada Inc | Mineral-polymer hybrid composition |
US20030158302A1 (en) * | 1999-12-09 | 2003-08-21 | Cyric Chaput | Mineral-polymer hybrid composition |
US6623963B1 (en) | 1999-12-20 | 2003-09-23 | Verigen Ag | Cellular matrix |
US7635390B1 (en) | 2000-01-14 | 2009-12-22 | Marctec, Llc | Joint replacement component having a modular articulating surface |
US6702821B2 (en) | 2000-01-14 | 2004-03-09 | The Bonutti 2003 Trust A | Instrumentation for minimally invasive joint replacement and methods for using same |
US6805695B2 (en) | 2000-04-04 | 2004-10-19 | Spinalabs, Llc | Devices and methods for annular repair of intervertebral discs |
DE60129007T2 (en) * | 2000-04-14 | 2008-02-28 | University Of Pittsburgh | REPRODUCTION OF SOFT AND BONE TISSUE FROM MUSCLE PREMATURE CELLS, AND RELATED COMPOSITIONS AND TREATMENT FORMS |
US6454803B1 (en) | 2000-05-23 | 2002-09-24 | Romo, Iii Thomas | External nasal valve batten implant device and method |
PT1294414E (en) * | 2000-06-29 | 2006-07-31 | Biosyntech Canada Inc | COMPOSITION AND METHOD FOR THE REPAIR AND REGENERATION OF CARTILAGE AND OTHER FABRICS |
US6719970B1 (en) | 2000-07-10 | 2004-04-13 | Alkermes Controlled Therapeutics, Inc. | Method of generating cartilage |
US6440141B1 (en) | 2000-07-24 | 2002-08-27 | Oratec Interventions, Inc. | Method and apparatus for treating osteochondral pathologies |
US8366787B2 (en) * | 2000-08-04 | 2013-02-05 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorbable scaffolds |
US6638312B2 (en) | 2000-08-04 | 2003-10-28 | Depuy Orthopaedics, Inc. | Reinforced small intestinal submucosa (SIS) |
US6599526B2 (en) * | 2000-08-18 | 2003-07-29 | The University Of North Texas Health Science Center At Fort Worth | Pericardial anti-adhesion patch |
WO2002017955A1 (en) * | 2000-08-30 | 2002-03-07 | University Of Delaware | Delivery system for heparin-binding growth factors |
ATE426357T1 (en) | 2000-09-14 | 2009-04-15 | Univ Leland Stanford Junior | ASSESSING THE CONDITION OF A JOINT AND PLANNING TREATMENT |
US7560280B2 (en) * | 2000-11-03 | 2009-07-14 | Kourion Therapeutics Gmbh | Human cord blood derived unrestricted somatic stem cells (USSC) |
US20090130066A1 (en) * | 2000-11-06 | 2009-05-21 | Gerigene Medical Corporation | Augmentation and repair of sphincter defects with cells including muscle cells |
CA2429168C (en) * | 2000-11-15 | 2010-06-08 | Bio Syntech Canada Inc. | Method for restoring a damaged or degenerated intervertebral disc |
CA2659484C (en) | 2000-11-20 | 2013-01-08 | Senorx, Inc. | Tissue site markers for in vivo imaging |
US6852330B2 (en) | 2000-12-21 | 2005-02-08 | Depuy Mitek, Inc. | Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
US6599323B2 (en) * | 2000-12-21 | 2003-07-29 | Ethicon, Inc. | Reinforced tissue implants and methods of manufacture and use |
US7192604B2 (en) * | 2000-12-22 | 2007-03-20 | Ethicon, Inc. | Implantable biodegradable devices for musculoskeletal repair or regeneration |
US7553662B2 (en) * | 2000-12-22 | 2009-06-30 | Keele University | Culturing tissue using magnetically generated mechanical stresses |
EP1355684B1 (en) * | 2000-12-28 | 2010-01-20 | Fidia Advanced Biopolymers S.R.L. | Use of a biological material containing three-dimensional scaffolds of hyaluronic acid derivatives for the preparation of implants in arthroscopy and kit for instruments for implanting said biological material by arthroscopy |
US6911202B2 (en) * | 2001-02-06 | 2005-06-28 | Abraham Amir | Cosmetic repair using cartilage producing cells and medical implants coated therewith |
CA2438904C (en) * | 2001-02-23 | 2012-09-04 | The University Of Pittsburgh | Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair |
US6827743B2 (en) * | 2001-02-28 | 2004-12-07 | Sdgi Holdings, Inc. | Woven orthopedic implants |
KR20010044624A (en) * | 2001-03-12 | 2001-06-05 | 정재호 | A process for preparing the scaffold and tissue engineered cartilage made from the scaffold |
US7029838B2 (en) | 2001-03-30 | 2006-04-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Prevascularized contructs for implantation to provide blood perfusion |
WO2002096268A2 (en) | 2001-05-25 | 2002-12-05 | Imaging Therapeutics, Inc. | Methods and compositions for articular resurfacing |
US9308091B2 (en) | 2001-05-25 | 2016-04-12 | Conformis, Inc. | Devices and methods for treatment of facet and other joints |
US20070083266A1 (en) | 2001-05-25 | 2007-04-12 | Vertegen, Inc. | Devices and methods for treating facet joints, uncovertebral joints, costovertebral joints and other joints |
US8439926B2 (en) | 2001-05-25 | 2013-05-14 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US8951260B2 (en) | 2001-05-25 | 2015-02-10 | Conformis, Inc. | Surgical cutting guide |
EP1416866A4 (en) * | 2001-07-16 | 2007-04-18 | Depuy Products Inc | Devices form naturally occurring biologically derived |
AU2002320512B2 (en) | 2001-07-16 | 2008-01-31 | Depuy Products, Inc. | Cartilage repair and regeneration device and method |
AU2002313694B2 (en) * | 2001-07-16 | 2007-08-30 | Depuy Products, Inc. | Cartilage repair apparatus and method |
WO2003007786A2 (en) | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Porous delivery scaffold and method |
US7819918B2 (en) | 2001-07-16 | 2010-10-26 | Depuy Products, Inc. | Implantable tissue repair device |
US7914808B2 (en) | 2001-07-16 | 2011-03-29 | Depuy Products, Inc. | Hybrid biologic/synthetic porous extracellular matrix scaffolds |
US8025896B2 (en) | 2001-07-16 | 2011-09-27 | Depuy Products, Inc. | Porous extracellular matrix scaffold and method |
IL144446A0 (en) * | 2001-07-19 | 2002-05-23 | Prochon Biotech Ltd | Plasma protein matrices and methods for their preparation |
KR100494265B1 (en) * | 2001-08-14 | 2005-06-13 | 메디포스트(주) | Composition for treatment of articular cartilage damage |
US7708741B1 (en) | 2001-08-28 | 2010-05-04 | Marctec, Llc | Method of preparing bones for knee replacement surgery |
AU2002337807A1 (en) * | 2001-10-04 | 2003-04-14 | Massachusetts Institute Of Technology | Effect of bone morphogenetic proteins on engineered cartilage |
US8308784B2 (en) | 2006-08-24 | 2012-11-13 | Jackson Streeter | Low level light therapy for enhancement of neurologic function of a patient affected by Parkinson's disease |
US9993659B2 (en) | 2001-11-01 | 2018-06-12 | Pthera, Llc | Low level light therapy for enhancement of neurologic function by altering axonal transport rate |
US10683494B2 (en) | 2001-11-01 | 2020-06-16 | Pthera LLC | Enhanced stem cell therapy and stem cell production through the administration of low level light energy |
US7534255B1 (en) | 2003-01-24 | 2009-05-19 | Photothera, Inc | Low level light therapy for enhancement of neurologic function |
US7303578B2 (en) | 2001-11-01 | 2007-12-04 | Photothera, Inc. | Device and method for providing phototherapy to the brain |
US10695577B2 (en) | 2001-12-21 | 2020-06-30 | Photothera, Inc. | Device and method for providing phototherapy to the heart |
US7316922B2 (en) | 2002-01-09 | 2008-01-08 | Photothera Inc. | Method for preserving organs for transplant |
WO2003072128A2 (en) * | 2002-02-22 | 2003-09-04 | Ebi, L.P. | Methods and compositions for treating bone or cartilage defects |
EP1485487A4 (en) * | 2002-03-12 | 2005-11-09 | Tissuegene Inc | Cartilage regeneration using chondrocyte and tgf-beta |
US7005127B2 (en) * | 2002-03-29 | 2006-02-28 | Tissuegene, Inc. | Mixed-cell gene therapy |
US7431922B2 (en) * | 2002-03-29 | 2008-10-07 | Tissuegene, Inc. | Bioadhesive directed somatic cell therapy |
CA2485350C (en) | 2002-04-08 | 2014-08-19 | Millenium Biologix Inc. | Automated tissue engineering system comprising sensors linked to a microprocessor |
US7223289B2 (en) * | 2002-04-16 | 2007-05-29 | Warsaw Orthopedic, Inc. | Annulus repair systems and techniques |
AU2003245251A1 (en) * | 2002-05-01 | 2003-11-17 | Verigen Ag | Injectable chondrocyte implant |
JP4067880B2 (en) * | 2002-06-17 | 2008-03-26 | オリンパス株式会社 | Cell culture method |
US7622562B2 (en) | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
DE60334224D1 (en) * | 2002-07-16 | 2010-10-28 | Biosyntech Canada Inc | COMPOSITION FOR THE MANUFACTURE OF CELL-COMPATIBLE, INJECTABLE, SELF-MORGING CHITOSAN SOLUTIONS FOR CAPTIVATING AND DISTRIBUTING LIVING CELLS OR BIOLOGICALLY ACTIVE FACTORS |
US20040062753A1 (en) * | 2002-09-27 | 2004-04-01 | Alireza Rezania | Composite scaffolds seeded with mammalian cells |
US20040136968A1 (en) * | 2002-09-27 | 2004-07-15 | Verigen Ag | Autologous cells on a support matrix for tissue repair |
DE60336002D1 (en) | 2002-10-07 | 2011-03-24 | Conformis Inc | MINIMALLY INVASIVE JOINT IMPLANT WITH A THREE-DIMENSIONAL GEOMETRY TAILORED TO THE JOINTS |
US7824701B2 (en) | 2002-10-18 | 2010-11-02 | Ethicon, Inc. | Biocompatible scaffold for ligament or tendon repair |
EP3075356B1 (en) | 2002-11-07 | 2023-07-05 | ConforMIS, Inc. | Method of selecting a meniscal implant |
US20060036158A1 (en) | 2003-11-17 | 2006-02-16 | Inrad, Inc. | Self-contained, self-piercing, side-expelling marking apparatus |
US20040127402A1 (en) * | 2002-12-27 | 2004-07-01 | Vad Vijay B. | Injectible composition and method for treating degenerative animal joints |
US8551100B2 (en) | 2003-01-15 | 2013-10-08 | Biomet Manufacturing, Llc | Instrumentation for knee resection |
US7837690B2 (en) | 2003-01-15 | 2010-11-23 | Biomet Manufacturing Corp. | Method and apparatus for less invasive knee resection |
US7887542B2 (en) | 2003-01-15 | 2011-02-15 | Biomet Manufacturing Corp. | Method and apparatus for less invasive knee resection |
US7789885B2 (en) | 2003-01-15 | 2010-09-07 | Biomet Manufacturing Corp. | Instrumentation for knee resection |
CA2514474C (en) | 2003-01-30 | 2014-05-06 | Avner Yayon | Freeze-dried fibrin matrices and methods for preparation thereof |
AU2003900620A0 (en) * | 2003-02-12 | 2003-02-27 | Australian Surgical Design And Manufacture Pty Limited | Arthroscopic chondrocyte implantation method and device |
US7642092B2 (en) * | 2003-03-03 | 2010-01-05 | Technion Research & Development Foundation Ltd. | Cultured cartilage/bone cells/tissue, method of generating same and uses thereof |
US7344555B2 (en) | 2003-04-07 | 2008-03-18 | The United States Of America As Represented By The Department Of Health And Human Services | Light promotes regeneration and functional recovery after spinal cord injury |
JP2006524072A (en) * | 2003-04-21 | 2006-10-26 | ベリーゲン アーゲー | Seeded tear-resistant scaffold |
US9617516B2 (en) * | 2003-04-25 | 2017-04-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Muscle-derived cells (MDCs) for promoting and enhancing nerve repair and regeneration |
US7067123B2 (en) * | 2003-04-29 | 2006-06-27 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
US7416546B2 (en) * | 2003-05-05 | 2008-08-26 | Boston Scientific Scimed, Inc. | Tissue patches and related delivery systems and methods |
US8034048B2 (en) * | 2003-05-05 | 2011-10-11 | Boston Scientific Scimed, Inc. | Tissue patches and related delivery systems and methods |
EP2860292B1 (en) | 2003-05-08 | 2020-07-22 | Tepha, Inc. | Polyhydroxyalkanoate medical textiles and fibers |
US7344716B2 (en) * | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US7429378B2 (en) * | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
US7553827B2 (en) * | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
US20040229878A1 (en) * | 2003-05-13 | 2004-11-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of P38 kinase |
US8273347B2 (en) * | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US7877133B2 (en) | 2003-05-23 | 2011-01-25 | Senorx, Inc. | Marker or filler forming fluid |
ES2597837T3 (en) | 2003-06-27 | 2017-01-23 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of manufacturing and using them |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
US8491883B2 (en) | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
US7875272B2 (en) | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
US8361467B2 (en) | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
US8257963B2 (en) * | 2007-06-01 | 2012-09-04 | Depuy Mitek, Inc. | Chondrocyte container and method of use |
US7897384B2 (en) * | 2003-09-08 | 2011-03-01 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
US7927599B2 (en) | 2003-09-08 | 2011-04-19 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
DE10349722A1 (en) | 2003-10-23 | 2005-06-16 | Beschorner, Katharina, Dr. | Composition for arthritis / arthritis treatment, in particular of joints |
US20050273002A1 (en) | 2004-06-04 | 2005-12-08 | Goosen Ryan L | Multi-mode imaging marker |
US7316822B2 (en) | 2003-11-26 | 2008-01-08 | Ethicon, Inc. | Conformable tissue repair implant capable of injection delivery |
US8895540B2 (en) * | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
US7901461B2 (en) * | 2003-12-05 | 2011-03-08 | Ethicon, Inc. | Viable tissue repair implants and methods of use |
US7488324B1 (en) | 2003-12-08 | 2009-02-10 | Biomet Manufacturing Corporation | Femoral guide for implanting a femoral knee prosthesis |
ATE515245T1 (en) | 2003-12-11 | 2011-07-15 | Isto Technologies Inc | PARTICLE CARTILAGE SYSTEM |
GB0329310D0 (en) * | 2003-12-18 | 2004-01-21 | Univ Keele | Method |
JP2007520462A (en) * | 2003-12-19 | 2007-07-26 | バイアセル インコーポレーティッド | Use of human umbilical cord blood-derived pluripotent cells for the treatment of diseases |
GB0402838D0 (en) * | 2004-02-10 | 2004-03-17 | Univ Belfast | Method |
JP2007537778A (en) * | 2004-03-09 | 2007-12-27 | オステオバイオロジックス, インコーポレイテッド | Graft scaffold in combination with self or allogeneic tissue |
US20070185585A1 (en) * | 2004-03-09 | 2007-08-09 | Brat Bracy | Implant Scaffold Combined With Autologous Tissue, Allogenic Tissue, Cultured Tissue, or combinations Thereof |
RU2252252C1 (en) * | 2004-04-09 | 2005-05-20 | Тепляшин Александр Сергеевич | Method for isolation of mesenchymal stem cells |
US8137686B2 (en) | 2004-04-20 | 2012-03-20 | Depuy Mitek, Inc. | Nonwoven tissue scaffold |
US8221780B2 (en) | 2004-04-20 | 2012-07-17 | Depuy Mitek, Inc. | Nonwoven tissue scaffold |
US8657881B2 (en) | 2004-04-20 | 2014-02-25 | Depuy Mitek, Llc | Meniscal repair scaffold |
WO2005105992A1 (en) * | 2004-04-21 | 2005-11-10 | New York Eye & Ear Infirmary | Chondrocyte culture formulations |
EP1740123A4 (en) * | 2004-04-26 | 2008-09-03 | Howmedica Osteonics Corp | Stent for avascular meniscal repair and regeneration |
US20050288796A1 (en) * | 2004-06-23 | 2005-12-29 | Hani Awad | Native soft tissue matrix for therapeutic applications |
US7632284B2 (en) | 2004-07-06 | 2009-12-15 | Tyco Healthcare Group Lp | Instrument kit and method for performing meniscal repair |
US8637065B2 (en) * | 2004-07-09 | 2014-01-28 | William Marsh Rice University | Dermis-derived cells for tissue engineering applications |
US8192759B2 (en) * | 2004-07-12 | 2012-06-05 | Isto Technologies, Inc. | Matrix made of polyester polymers entangled with hyaluronic polymers useful for supporting tissue repair |
US8512730B2 (en) * | 2004-07-12 | 2013-08-20 | Isto Technologies, Inc. | Methods of tissue repair and compositions therefor |
US20090181092A1 (en) * | 2004-07-16 | 2009-07-16 | Spinal Restoration, Inc. | Methods for Treating Joints and Discs with a Carrier Matrix and Cells |
US7335508B2 (en) * | 2004-07-22 | 2008-02-26 | Prochon Biotech Ltd. | Porous plasma protein matrices and methods for preparation thereof |
ES2362217T3 (en) | 2004-08-03 | 2011-06-29 | Tepha, Inc. | NON-RIZED POLYHYDROXIALCANOATE SUTURES. |
US7785582B2 (en) * | 2004-09-07 | 2010-08-31 | Johnson Lanny L | Use of synovium and omentum for tissue engineering |
US8182806B2 (en) * | 2004-09-07 | 2012-05-22 | Johnson Lanny L | Synovial villi for use with tissue engineering |
CA2581328A1 (en) * | 2004-09-21 | 2006-03-30 | Massachusetts Institute Of Technology | Gradient scaffolding and methods of producing the same |
US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
US20060111778A1 (en) * | 2004-10-29 | 2006-05-25 | Michalow Alexander E | Methods of promoting healing of cartilage defects and method of causing stem cells to differentiate by the articular chondrocyte pathway |
US7513866B2 (en) | 2004-10-29 | 2009-04-07 | Depuy Products, Inc. | Intestine processing device and associated method |
US20060097422A1 (en) * | 2004-11-08 | 2006-05-11 | Diamond Andrew J | Method for performing surgery and appliances produced thereby |
US9981063B2 (en) * | 2004-11-24 | 2018-05-29 | Mayo Foundation For Medical Education And Research | Biosynthetic composite for osteochondral defect repair |
CA2589041C (en) | 2004-12-23 | 2019-08-20 | Ethicon, Incorporated | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US7695479B1 (en) | 2005-04-12 | 2010-04-13 | Biomet Manufacturing Corp. | Femoral sizer |
US10357328B2 (en) | 2005-04-20 | 2019-07-23 | Bard Peripheral Vascular, Inc. and Bard Shannon Limited | Marking device with retractable cannula |
US7815926B2 (en) | 2005-07-11 | 2010-10-19 | Musculoskeletal Transplant Foundation | Implant for articular cartilage repair |
KR100774089B1 (en) * | 2005-07-20 | 2007-11-06 | 세원셀론텍(주) | Simple Method of Autologous Chondrocyte Transplantation ? Injectable Chondrocyte Transplantation |
US8048297B2 (en) | 2005-08-23 | 2011-11-01 | Biomet Biologics, Llc | Method and apparatus for collecting biological materials |
EP1916964A4 (en) | 2005-08-26 | 2015-11-04 | Zimmer Inc | Implants and methods for repair, replacement and treatment of joint disease |
EP1924146A4 (en) * | 2005-09-02 | 2012-05-02 | Interface Biotech As | A method for cell implantation |
US7927630B2 (en) * | 2005-09-12 | 2011-04-19 | Johnson Lanny L | Use of autologous sediment from fluid aspirates as vehicles for drug delivery |
US8518349B2 (en) | 2005-09-12 | 2013-08-27 | Lanny Johnson | Use of autologous sediment from fluid aspirates as vehicles for drug delivery |
US20070065415A1 (en) * | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
WO2007035778A2 (en) | 2005-09-19 | 2007-03-29 | Histogenics Corporation | Cell-support matrix and a method for preparation thereof |
CA2562580C (en) | 2005-10-07 | 2014-04-29 | Inrad, Inc. | Drug-eluting tissue marker |
CA2628244A1 (en) * | 2005-11-04 | 2007-05-10 | Bio Syntech Canada Inc. | Gel formation of polyelectrolyte aqueous solutions by thermally induced changes in ionization state |
EP2302037A1 (en) * | 2005-11-10 | 2011-03-30 | Carticure Ltd. | Method for non-autologous cartilage regeneration |
CA2631520A1 (en) * | 2005-12-07 | 2007-06-14 | Isto Technologies, Inc. | Cartilage repair methods |
ES2642844T3 (en) | 2005-12-16 | 2017-11-20 | DePuy Synthes Products, Inc. | Compositions and methods to inhibit an adverse immune response in histocompatibility transplantation that do not match |
JP5179376B2 (en) | 2005-12-19 | 2013-04-10 | エシコン・インコーポレイテッド | In vitro growth of postpartum-extracted cells in roller bottles |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
CA2640185A1 (en) * | 2006-01-24 | 2007-08-02 | Christopher J. Centeno | Mesenchymal stem cell isolation and transplantation method and system to be used in a clinical setting |
US7776043B2 (en) * | 2006-01-26 | 2010-08-17 | Warsaw Orthopedic, Inc. | Osteochondral implant fixation procedure and bone dilator used in same |
US7575589B2 (en) | 2006-01-30 | 2009-08-18 | Photothera, Inc. | Light-emitting device and method for providing phototherapy to the brain |
US20090254154A1 (en) | 2008-03-18 | 2009-10-08 | Luis De Taboada | Method and apparatus for irradiating a surface with pulsed light |
US10357662B2 (en) | 2009-02-19 | 2019-07-23 | Pthera LLC | Apparatus and method for irradiating a surface with light |
EP1981409B1 (en) | 2006-02-06 | 2017-01-11 | ConforMIS, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US8623026B2 (en) | 2006-02-06 | 2014-01-07 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief |
US9289253B2 (en) | 2006-02-27 | 2016-03-22 | Biomet Manufacturing, Llc | Patient-specific shoulder guide |
US20150335438A1 (en) | 2006-02-27 | 2015-11-26 | Biomet Manufacturing, Llc. | Patient-specific augments |
US9173661B2 (en) | 2006-02-27 | 2015-11-03 | Biomet Manufacturing, Llc | Patient specific alignment guide with cutting surface and laser indicator |
US9345548B2 (en) | 2006-02-27 | 2016-05-24 | Biomet Manufacturing, Llc | Patient-specific pre-operative planning |
US8070752B2 (en) | 2006-02-27 | 2011-12-06 | Biomet Manufacturing Corp. | Patient specific alignment guide and inter-operative adjustment |
US8591516B2 (en) | 2006-02-27 | 2013-11-26 | Biomet Manufacturing, Llc | Patient-specific orthopedic instruments |
US10278711B2 (en) | 2006-02-27 | 2019-05-07 | Biomet Manufacturing, Llc | Patient-specific femoral guide |
US8407067B2 (en) | 2007-04-17 | 2013-03-26 | Biomet Manufacturing Corp. | Method and apparatus for manufacturing an implant |
US9339278B2 (en) | 2006-02-27 | 2016-05-17 | Biomet Manufacturing, Llc | Patient-specific acetabular guides and associated instruments |
US9907659B2 (en) | 2007-04-17 | 2018-03-06 | Biomet Manufacturing, Llc | Method and apparatus for manufacturing an implant |
US8603180B2 (en) | 2006-02-27 | 2013-12-10 | Biomet Manufacturing, Llc | Patient-specific acetabular alignment guides |
US9918740B2 (en) | 2006-02-27 | 2018-03-20 | Biomet Manufacturing, Llc | Backup surgical instrument system and method |
US9113971B2 (en) | 2006-02-27 | 2015-08-25 | Biomet Manufacturing, Llc | Femoral acetabular impingement guide |
US7780672B2 (en) | 2006-02-27 | 2010-08-24 | Biomet Manufacturing Corp. | Femoral adjustment device and associated method |
US7695520B2 (en) | 2006-05-31 | 2010-04-13 | Biomet Manufacturing Corp. | Prosthesis and implementation system |
US9795399B2 (en) | 2006-06-09 | 2017-10-24 | Biomet Manufacturing, Llc | Patient-specific knee alignment guide and associated method |
KR100803576B1 (en) * | 2006-06-14 | 2008-02-15 | 주식회사 인피트론 | A composition for transplant comprising adipose stem cells and adipocytes |
US20080294039A1 (en) * | 2006-08-04 | 2008-11-27 | Senorx, Inc. | Assembly with hemostatic and radiographically detectable pellets |
EP2051646A4 (en) * | 2006-08-07 | 2014-06-11 | Howmedica Osteonics Corp | Insertion system for implanting a medical device and surgical methods |
US20080033487A1 (en) * | 2006-08-07 | 2008-02-07 | Bioduct, Llc | Medical device for repair of tissue and method for implantation and fixation |
ES2332864T1 (en) * | 2006-09-07 | 2010-02-15 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | PROCEDURE TO TREAT BONE CANCER. |
US8064987B2 (en) | 2006-10-23 | 2011-11-22 | C. R. Bard, Inc. | Breast marker |
US7943683B2 (en) | 2006-12-01 | 2011-05-17 | Tepha, Inc. | Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers |
US20080138414A1 (en) * | 2006-12-08 | 2008-06-12 | Smith & Nephew, Inc. | Methods of Regenerating Cartilage |
US9579077B2 (en) | 2006-12-12 | 2017-02-28 | C.R. Bard, Inc. | Multiple imaging mode tissue marker |
US8323642B2 (en) * | 2006-12-13 | 2012-12-04 | Depuy Mitek, Inc. | Tissue fusion method using collagenase for repair of soft tissue |
EP2101670B1 (en) | 2006-12-18 | 2013-07-31 | C.R.Bard, Inc. | Biopsy marker with in situ-generated imaging properties |
US8163549B2 (en) * | 2006-12-20 | 2012-04-24 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
WO2008100442A1 (en) * | 2007-02-09 | 2008-08-21 | Biomet Biologics, Inc. | Treatment of tissue defects with a therapeutic composition |
EP2591756A1 (en) | 2007-02-14 | 2013-05-15 | Conformis, Inc. | Implant device and method for manufacture |
US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
US8034014B2 (en) | 2007-03-06 | 2011-10-11 | Biomet Biologics, Llc | Angiogenesis initation and growth |
CA2684040C (en) | 2007-04-12 | 2016-12-06 | Isto Technologies, Inc. | Method of forming an implant using a mold that mimics the shape of the tissue defect site and implant formed therefrom |
EP2607477B1 (en) | 2007-05-03 | 2020-09-23 | The Brigham and Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
US20080281419A1 (en) * | 2007-05-10 | 2008-11-13 | Matheny Robert G | Breast implants and compositions of extracellular matrix |
US20090004253A1 (en) * | 2007-06-29 | 2009-01-01 | Brown Laura J | Composite device for the repair or regeneration of tissue |
US9095562B2 (en) | 2007-07-05 | 2015-08-04 | Regenerative Sciences, Inc. | Methods and compositions for optimized expansion and implantation of mesenchymal stem cells |
CN102036688B (en) | 2007-10-05 | 2014-07-02 | 伊西康公司 | Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells |
WO2009085969A2 (en) | 2007-12-19 | 2009-07-09 | Regenerative Sciences, Llc | Compositions and methods to promote implantation and engrafment of stem cells |
US8236538B2 (en) | 2007-12-20 | 2012-08-07 | Advanced Technologies And Regenerative Medicine, Llc | Methods for sterilizing materials containing biologically active agents |
US8986696B2 (en) | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
US8311610B2 (en) | 2008-01-31 | 2012-11-13 | C. R. Bard, Inc. | Biopsy tissue marker |
US8753690B2 (en) | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
EP2620139B1 (en) | 2008-02-27 | 2016-07-20 | Biomet Biologics, LLC | Interleukin-1 receptor antagonist rich solutions |
EP2265220A1 (en) | 2008-03-05 | 2010-12-29 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
WO2009111626A2 (en) | 2008-03-05 | 2009-09-11 | Conformis, Inc. | Implants for altering wear patterns of articular surfaces |
WO2009114785A2 (en) | 2008-03-14 | 2009-09-17 | Regenerative Sciences, Inc. | Compositions and methods for cartilage repair |
US9199003B2 (en) * | 2008-08-18 | 2015-12-01 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof |
US7848035B2 (en) | 2008-09-18 | 2010-12-07 | Photothera, Inc. | Single-use lens assembly |
US9327061B2 (en) | 2008-09-23 | 2016-05-03 | Senorx, Inc. | Porous bioabsorbable implant |
US8163022B2 (en) | 2008-10-14 | 2012-04-24 | Anulex Technologies, Inc. | Method and apparatus for the treatment of the intervertebral disc annulus |
WO2010048418A1 (en) * | 2008-10-22 | 2010-04-29 | The Trustees Of Columbia University In The City Of New York | Cartilage regeneration without cell transplantation |
KR20190084341A (en) | 2008-11-25 | 2019-07-16 | 코오롱 티슈진 인크. | Primed cell therapy |
JP2012510874A (en) | 2008-12-05 | 2012-05-17 | リジェネレイティブ サイエンシーズ, エルエルシー | Methods and compositions for promoting repair of avascular tissue |
US20100168022A1 (en) * | 2008-12-11 | 2010-07-01 | Centeno Christopher J | Use of In-Vitro Culture to Design or Test Personalized Treatment Regimens |
US20100151114A1 (en) * | 2008-12-17 | 2010-06-17 | Zimmer, Inc. | In-line treatment of yarn prior to creating a fabric |
EP2379088B1 (en) | 2008-12-19 | 2018-02-28 | DePuy Synthes Products, Inc. | Treatment of lung and pulmonary diseases and disorders |
US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
EP3005971B1 (en) | 2008-12-30 | 2023-04-26 | C. R. Bard, Inc. | Marker delivery device for tissue marker placement |
US20100291182A1 (en) * | 2009-01-21 | 2010-11-18 | Arsenal Medical, Inc. | Drug-Loaded Fibers |
WO2010099231A2 (en) | 2009-02-24 | 2010-09-02 | Conformis, Inc. | Automated systems for manufacturing patient-specific orthopedic implants and instrumentation |
US9017334B2 (en) | 2009-02-24 | 2015-04-28 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
US8808297B2 (en) | 2009-02-24 | 2014-08-19 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
US8808303B2 (en) | 2009-02-24 | 2014-08-19 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
BRPI1013409A2 (en) | 2009-03-26 | 2018-01-16 | Advanced Tech And Regenerative Medicine Llc | human umbilical cord tissue cells as therapy for alzheimer's disease |
WO2010121147A1 (en) | 2009-04-16 | 2010-10-21 | Conformis, Inc. | Patient-specific joint arthroplasty devices for ligament repair |
US20100316614A1 (en) * | 2009-06-16 | 2010-12-16 | Northwestern University | Compositions and methods for urinary bladder regeneration |
US9044580B2 (en) | 2009-08-24 | 2015-06-02 | Arsenal Medical, Inc. | In-situ forming foams with outer layer |
US9173817B2 (en) | 2009-08-24 | 2015-11-03 | Arsenal Medical, Inc. | In situ forming hemostatic foam implants |
US10420862B2 (en) | 2009-08-24 | 2019-09-24 | Aresenal AAA, LLC. | In-situ forming foams for treatment of aneurysms |
US20110202016A1 (en) * | 2009-08-24 | 2011-08-18 | Arsenal Medical, Inc. | Systems and methods relating to polymer foams |
US9763875B2 (en) | 2009-08-27 | 2017-09-19 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
US20110052561A1 (en) * | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
US20110054929A1 (en) * | 2009-09-01 | 2011-03-03 | Cell Solutions Colorado Llc | Stem Cell Marketplace |
US8377432B2 (en) * | 2009-09-02 | 2013-02-19 | Khay-Yong Saw | Method and composition for neochondrogenesis |
US9113950B2 (en) | 2009-11-04 | 2015-08-25 | Regenerative Sciences, Llc | Therapeutic delivery device |
US8460319B2 (en) | 2010-01-11 | 2013-06-11 | Anulex Technologies, Inc. | Intervertebral disc annulus repair system and method |
KR20120113265A (en) | 2010-01-15 | 2012-10-12 | 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 | Use of vanadium compounds to accelerate bone healing |
EP2926821B1 (en) | 2010-03-05 | 2019-12-25 | Tissue Genesis, LLC | Compositions to support tissue integration and inosculation of transplanted tissue and transplanted engineered penile tissue with adipose stromal cells |
US8697111B2 (en) * | 2010-05-12 | 2014-04-15 | Covidien Lp | Osteochondral implant comprising osseous phase and chondral phase |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
EP2625577B1 (en) | 2010-10-08 | 2019-06-26 | Terumo BCT, Inc. | Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
US9968376B2 (en) | 2010-11-29 | 2018-05-15 | Biomet Manufacturing, Llc | Patient-specific orthopedic instruments |
US20140322292A1 (en) | 2010-12-10 | 2014-10-30 | Rutgers, The State University Of New Jersey | Insulin-mimetics as therapeutic adjuncts for bone regeneration |
AU2011352928B2 (en) | 2010-12-27 | 2017-02-02 | Stroma Cell Therapeutics, Llc | Ultrasonic cavitation derived stromal or mesenchymal vascular extracts and cells derived therefrom obtained from adipose tissue and use thereof |
US9034240B2 (en) | 2011-01-31 | 2015-05-19 | Arsenal Medical, Inc. | Electrospinning process for fiber manufacture |
US8968626B2 (en) | 2011-01-31 | 2015-03-03 | Arsenal Medical, Inc. | Electrospinning process for manufacture of multi-layered structures |
US9194058B2 (en) | 2011-01-31 | 2015-11-24 | Arsenal Medical, Inc. | Electrospinning process for manufacture of multi-layered structures |
EP2754419B1 (en) | 2011-02-15 | 2024-02-07 | ConforMIS, Inc. | Patient-adapted and improved orthopedic implants |
US9241745B2 (en) | 2011-03-07 | 2016-01-26 | Biomet Manufacturing, Llc | Patient-specific femoral version guide |
US8834928B1 (en) | 2011-05-16 | 2014-09-16 | Musculoskeletal Transplant Foundation | Tissue-derived tissugenic implants, and methods of fabricating and using same |
US20130071360A1 (en) | 2011-06-29 | 2013-03-21 | Biorestorative Therapies, Inc. | Brown Fat Cell Compositions and Methods |
KR101360162B1 (en) * | 2011-06-30 | 2014-02-11 | 김지형 | A Method for Proliferating Chondrocytes For Meniscus Transplantation |
US9931348B2 (en) * | 2011-07-06 | 2018-04-03 | Rutgers, The State University Of New Jersey | Vanadium compounds as therapeutic adjuncts for cartilage injury and repair |
US8993831B2 (en) | 2011-11-01 | 2015-03-31 | Arsenal Medical, Inc. | Foam and delivery system for treatment of postpartum hemorrhage |
MX362198B (en) | 2011-12-23 | 2019-01-08 | Depuy Synthes Products Llc | Detection of human umbilical cord tissue-derived cells. |
US9486226B2 (en) | 2012-04-18 | 2016-11-08 | Conformis, Inc. | Tibial guides, tools, and techniques for resecting the tibial plateau |
US9675471B2 (en) | 2012-06-11 | 2017-06-13 | Conformis, Inc. | Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components |
US10245306B2 (en) | 2012-11-16 | 2019-04-02 | Isto Technologies Ii, Llc | Flexible tissue matrix and methods for joint repair |
US20140178343A1 (en) | 2012-12-21 | 2014-06-26 | Jian Q. Yao | Supports and methods for promoting integration of cartilage tissue explants |
WO2014117107A1 (en) | 2013-01-28 | 2014-07-31 | Cartiva, Inc. | Systems and methods for orthopedic repair |
US9737294B2 (en) | 2013-01-28 | 2017-08-22 | Cartiva, Inc. | Method and system for orthopedic repair |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
USD716451S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD715942S1 (en) | 2013-09-24 | 2014-10-21 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD716450S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD715442S1 (en) | 2013-09-24 | 2014-10-14 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
EP3074507B1 (en) | 2013-11-26 | 2022-01-05 | Biomet Biologics, LLC | Methods of mediating macrophage phenotypes |
EP3122866B1 (en) | 2014-03-25 | 2019-11-20 | Terumo BCT, Inc. | Passive replacement of media |
WO2016025329A1 (en) | 2014-08-15 | 2016-02-18 | Tepha, Inc. | Self-retaining sutures of poly-4-hydroxybutyrate and copolymers thereof |
ES2877181T3 (en) | 2014-09-23 | 2021-11-16 | Cytexx Therapeutics Inc | Articular cartilage repair |
US20160090569A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled Feed |
US10179191B2 (en) | 2014-10-09 | 2019-01-15 | Isto Technologies Ii, Llc | Flexible tissue matrix and methods for joint repair |
US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
WO2016094669A1 (en) | 2014-12-11 | 2016-06-16 | Tepha, Inc. | Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof |
US10626521B2 (en) | 2014-12-11 | 2020-04-21 | Tepha, Inc. | Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof |
US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
CA3177726A1 (en) | 2015-05-21 | 2016-11-24 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US10022231B2 (en) * | 2016-07-22 | 2018-07-17 | Cytex Therapeutics, Inc. | Articular cartilage repair |
US10722310B2 (en) | 2017-03-13 | 2020-07-28 | Zimmer Biomet CMF and Thoracic, LLC | Virtual surgery planning system and method |
JP7393945B2 (en) | 2017-03-31 | 2023-12-07 | テルモ ビーシーティー、インコーポレーテッド | cell proliferation |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
CN115216450A (en) | 2017-09-01 | 2022-10-21 | 隆萨沃克斯维尔股份有限公司 | End-to-end cell therapy automation |
JP2022514761A (en) | 2018-12-21 | 2022-02-15 | ロンザ ウォーカーズヴィル,インコーポレーテッド | Automatic production method of viral vector |
CN113366099A (en) | 2018-12-21 | 2021-09-07 | 奥克泰生物科技股份有限公司 | Carousel for modular bio-production units |
WO2020132743A1 (en) | 2018-12-28 | 2020-07-02 | Octane Biotech Inc. | Cell culture and tissue engineering systems with controlled environmental zones |
SG11202108473XA (en) | 2019-02-08 | 2021-09-29 | Lonza Walkersville Inc | Cell concentration methods and devices for use in automated bioreactors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4846835A (en) * | 1987-06-15 | 1989-07-11 | Grande Daniel A | Technique for healing lesions in cartilage |
WO1993015694A1 (en) * | 1992-02-14 | 1993-08-19 | Board Of Regents, The University Of Texas System | Multi-phase bioerodible implant/carrier and method of manufacturing and using same |
US5376118A (en) * | 1989-05-10 | 1994-12-27 | United States Surgical Corporation | Support material for cell impregnation |
US5460959A (en) * | 1987-09-11 | 1995-10-24 | Whitehead Institute For Biomedical Research | Transduced fibroblasts |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4520821A (en) * | 1982-04-30 | 1985-06-04 | The Regents Of The University Of California | Growing of long-term biological tissue correction structures in vivo |
US4609551A (en) * | 1984-03-20 | 1986-09-02 | Arnold Caplan | Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites |
US5160490A (en) * | 1986-04-18 | 1992-11-03 | Marrow-Tech Incorporated | Three-dimensional cell and tissue culture apparatus |
US5266480A (en) * | 1986-04-18 | 1993-11-30 | Advanced Tissue Sciences, Inc. | Three-dimensional skin culture system |
US5032508A (en) * | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US5510254A (en) * | 1986-04-18 | 1996-04-23 | Advanced Tissue Sciences, Inc. | Three dimensional cell and tissue culture system |
US4963489A (en) * | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US5041138A (en) * | 1986-11-20 | 1991-08-20 | Massachusetts Institute Of Technology | Neomorphogenesis of cartilage in vivo from cell culture |
US5306311A (en) * | 1987-07-20 | 1994-04-26 | Regen Corporation | Prosthetic articular cartilage |
US5226914A (en) * | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
US5197985A (en) * | 1990-11-16 | 1993-03-30 | Caplan Arnold I | Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells |
US5206023A (en) * | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
US5478739A (en) * | 1992-10-23 | 1995-12-26 | Advanced Tissue Sciences, Inc. | Three-dimensional stromal cell and tissue culture system |
US5723331A (en) * | 1994-05-05 | 1998-03-03 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
-
1996
- 1996-02-21 US US08/604,284 patent/US5842477A/en not_active Expired - Lifetime
-
1997
- 1997-02-20 CA CA002247158A patent/CA2247158A1/en not_active Abandoned
- 1997-02-20 NZ NZ331517A patent/NZ331517A/en unknown
- 1997-02-20 KR KR1019980706539A patent/KR19990087147A/en not_active Application Discontinuation
- 1997-02-20 WO PCT/US1997/002909 patent/WO1997030662A1/en not_active Application Discontinuation
- 1997-02-20 AU AU19731/97A patent/AU715282B2/en not_active Ceased
- 1997-02-20 EP EP97907835A patent/EP0955959A1/en not_active Withdrawn
- 1997-02-20 JP JP9530388A patent/JP2000505338A/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4846835A (en) * | 1987-06-15 | 1989-07-11 | Grande Daniel A | Technique for healing lesions in cartilage |
US5460959A (en) * | 1987-09-11 | 1995-10-24 | Whitehead Institute For Biomedical Research | Transduced fibroblasts |
US5376118A (en) * | 1989-05-10 | 1994-12-27 | United States Surgical Corporation | Support material for cell impregnation |
WO1993015694A1 (en) * | 1992-02-14 | 1993-08-19 | Board Of Regents, The University Of Texas System | Multi-phase bioerodible implant/carrier and method of manufacturing and using same |
Non-Patent Citations (2)
Title |
---|
CALCIFIED TISSUE INTERNATIONAL, 1993, Vol. 53, TANIGUCHI Y. et al., "Transforming Growth Factor beta1-Induced Cellular Heterogeneity in the Periosteum of Rat Bones", pages 122-126. * |
See also references of EP0955959A4 * |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569172B2 (en) | 1996-08-30 | 2003-05-27 | Verigen Transplantation Service International (Vtsi) | Method, instruments, and kit for autologous transplantation |
US7137989B2 (en) | 1996-08-30 | 2006-11-21 | Verigen Ag | Method, instruments, and kit for autologous transplantation |
US7048750B2 (en) | 1996-08-30 | 2006-05-23 | Verigen Ag | Method, instruments, and kits for autologous transplantation |
US6599300B2 (en) | 1996-08-30 | 2003-07-29 | Verigen Transplantation Service International (Vtsi) | Method, instruments, and kit for autologous transplantation |
US6599301B2 (en) | 1996-08-30 | 2003-07-29 | Verrgen Transplantation Service International (Vtsi) | Method, instruments, and kit for autologous transplantation |
US6283980B1 (en) | 1996-08-30 | 2001-09-04 | Verigen Transplantation Services Internt'l | Method, instruments, and kit for autologous transplantation |
US6592598B2 (en) | 1996-08-30 | 2003-07-15 | Verigen Transplantation Service International (Vtsi) | Method, instruments, and kit for autologous transplantation |
US6379367B1 (en) | 1996-08-30 | 2002-04-30 | Verigen Transplantation Service International (Vtsi) Ag | Method instruments and kit for autologous transplantation |
US6592599B2 (en) | 1996-08-30 | 2003-07-15 | Verigen Transplantation Service International (Vtsi) | Method, instruments, and kit for autologous transplantation |
JP2009102393A (en) * | 1997-02-07 | 2009-05-14 | Stryker Corp | Matrix-free osteogenic devices, implants and methods of use thereof |
WO1998042389A1 (en) * | 1997-03-25 | 1998-10-01 | Peter Villeneuve | Materials for healing cartilage and bone defects |
US6077987A (en) * | 1997-09-04 | 2000-06-20 | North Shore-Long Island Jewish Research Institute | Genetic engineering of cells to enhance healing and tissue regeneration |
US6398816B1 (en) | 1997-09-04 | 2002-06-04 | North Shore-Long Island Jewish Research Institute | Genetic engineering of cells to enhance healing and tissue regeneration |
WO1999011789A1 (en) * | 1997-09-04 | 1999-03-11 | North Shore University Hospital Research Corporation | Genetic engineering of cells to enhance healing and tissue regeneration |
WO1999025396A3 (en) * | 1997-11-17 | 1999-07-29 | Univ Michigan | Hybrid tissues for tissue engineering |
WO1999025396A2 (en) * | 1997-11-17 | 1999-05-27 | The Regents Of The University Of Michigan | Hybrid tissues for tissue engineering |
WO2000009179A3 (en) * | 1998-08-14 | 2000-06-02 | Verigen Transplantation Serv | Methods, instruments and materials for chondrocyte cell transplantation |
US6866668B2 (en) | 1998-08-14 | 2005-03-15 | Verigen Transplantation Service International (“VTSL”) AG | Methods, instruments and materials for chondrocyte cell transplantation |
EP1656960A1 (en) * | 1998-08-14 | 2006-05-17 | Verigen AG | Methods, instruments and materials for chondrocyte cell transplantation |
WO2000009179A2 (en) * | 1998-08-14 | 2000-02-24 | Verigen Transplantation Service International (Vtsi) Ag | Methods, instruments and materials for chondrocyte cell transplantation |
US8137689B1 (en) | 1999-11-11 | 2012-03-20 | Zimmer Gmbh | Transplant/implant device and method for its production |
JP2015128633A (en) * | 2000-04-25 | 2015-07-16 | メゾブラスト・インターナショナル・ソシエテ・ア・レスポンサビリテ・リミテ | Usage of mesenchymal stem cell to pharmaceutical composition preparation for recovery of animal joint |
US9050178B2 (en) | 2000-04-25 | 2015-06-09 | Mesoblast International Sàrl | Joint repair using mesenchymal stem cells |
JP2016216487A (en) * | 2000-04-25 | 2016-12-22 | メゾブラスト・インターナショナル・ソシエテ・ア・レスポンサビリテ・リミテ | Method of using mesenchymal stem cells for preparing pharmaceutical compositions for joint repair in animal |
US9814580B2 (en) | 2000-04-25 | 2017-11-14 | Mesoblast International Sarl | Joint repair using mesenchymal stem cells |
JP2012210437A (en) * | 2000-04-25 | 2012-11-01 | Osiris Therapeutics Inc | Method for using mesenchymal stem cells in preparing medical composition for mammal joint repair |
EP1276486B1 (en) * | 2000-04-25 | 2010-11-24 | Osiris Therapeutics, Inc. | Joint repair using mesenchymal stem cells |
EP2071020A3 (en) * | 2000-07-29 | 2014-12-31 | Smith&Nephew PLC | Tissue Implant |
WO2002010348A2 (en) * | 2000-07-29 | 2002-02-07 | Smith & Nephew Plc | Tissue implant for cartilage repair |
WO2002010348A3 (en) * | 2000-07-29 | 2002-09-06 | Smith & Nephew | Tissue implant for cartilage repair |
AU2007203472B2 (en) * | 2000-07-29 | 2011-07-14 | Smith & Nephew Plc | Tissue implant for cartilage repair |
AU2001275746B2 (en) * | 2000-07-29 | 2007-04-26 | Smith & Nephew Plc | Tissue implant for cartilage repair |
US9452238B2 (en) | 2000-07-29 | 2016-09-27 | Smith & Nephew LLP | Tissue implant |
US8691259B2 (en) | 2000-12-21 | 2014-04-08 | Depuy Mitek, Llc | Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
EP1416879A2 (en) * | 2001-07-16 | 2004-05-12 | Depuy Products, Inc. | Unitary surgical device and method |
AU2002354911B2 (en) * | 2001-07-16 | 2007-08-30 | Depuy Products, Inc. | Meniscus regeneration device and method |
EP1416888A4 (en) * | 2001-07-16 | 2007-04-25 | Depuy Products Inc | Meniscus regeneration device and method |
EP1416879A4 (en) * | 2001-07-16 | 2007-04-25 | Depuy Products Inc | Unitary surgical device and method |
EP1416888A2 (en) * | 2001-07-16 | 2004-05-12 | Depuy Products, Inc. | Meniscus regeneration device and method |
US7445793B2 (en) | 2002-09-09 | 2008-11-04 | Kaneka Corporation | Support for tissue regeneration and process for producing the same |
US9511171B2 (en) | 2002-10-18 | 2016-12-06 | Depuy Mitek, Llc | Biocompatible scaffolds with tissue fragments |
US10603408B2 (en) | 2002-10-18 | 2020-03-31 | DePuy Synthes Products, Inc. | Biocompatible scaffolds with tissue fragments |
US8173162B2 (en) | 2003-02-26 | 2012-05-08 | Zimmer Orthobiologics, Inc. | Preparation for repairing cartilage tissue, especially articular cartilage defects |
US8895045B2 (en) | 2003-03-07 | 2014-11-25 | Depuy Mitek, Llc | Method of preparation of bioabsorbable porous reinforced tissue implants and implants thereof |
US9486558B2 (en) | 2003-03-27 | 2016-11-08 | Locate Therapeutics Limited | Porous matrix |
US9211362B2 (en) | 2003-06-30 | 2015-12-15 | Depuy Mitek, Llc | Scaffold for connective tissue repair |
US10583220B2 (en) | 2003-08-11 | 2020-03-10 | DePuy Synthes Products, Inc. | Method and apparatus for resurfacing an articular surface |
US11395865B2 (en) | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
US8945535B2 (en) | 2005-09-20 | 2015-02-03 | Zimmer Orthobiologics, Inc. | Implant for the repair of a cartilage defect and method for manufacturing the implant |
US20100189712A1 (en) * | 2006-11-17 | 2010-07-29 | Cytograft Tissue Engineering, Inc. | Preparation And Use Of Cell-Synthesized Threads |
US7871440B2 (en) | 2006-12-11 | 2011-01-18 | Depuy Products, Inc. | Unitary surgical device and method |
US9238090B1 (en) | 2014-12-24 | 2016-01-19 | Fettech, Llc | Tissue-based compositions |
US11938246B2 (en) | 2014-12-24 | 2024-03-26 | Fettech, Llc | Tissue-based compositions and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
AU715282B2 (en) | 2000-01-20 |
NZ331517A (en) | 2000-01-28 |
AU1973197A (en) | 1997-09-10 |
JP2000505338A (en) | 2000-05-09 |
EP0955959A1 (en) | 1999-11-17 |
US5842477A (en) | 1998-12-01 |
CA2247158A1 (en) | 1997-08-28 |
KR19990087147A (en) | 1999-12-15 |
EP0955959A4 (en) | 1999-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5842477A (en) | Method for repairing cartilage | |
US11357889B2 (en) | Native soft tissue matrix for therapeutic applications | |
US7078232B2 (en) | Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof | |
US4904259A (en) | Compositions and methods for repair of cartilage and bone | |
Radice et al. | Hyaluronan‐based biopolymers as delivery vehicles for bone‐marrow‐derived mesenchymal progenitors | |
US5919702A (en) | Production of cartilage tissue using cells isolated from Wharton's jelly | |
US8796019B2 (en) | Tissue repair with multipotent cells | |
US5041138A (en) | Neomorphogenesis of cartilage in vivo from cell culture | |
US6482231B1 (en) | Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative | |
US5736372A (en) | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure | |
JP2003510108A (en) | Biological joint structures | |
CA2435767A1 (en) | Compositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells | |
Clark et al. | Porous implants as drug delivery vehicles to augment host tissue integration | |
Rotter et al. | Behavior of tissue-engineered human cartilage after transplantation into nude mice | |
Vacanti et al. | Structural tissue engineering | |
Petite et al. | Marrow stromal stem cells for repairing the skeleton | |
Yannas | Regenerative medicine II: clinical and preclinical applications | |
CA1341078C (en) | Compositions and methods for repairs of cartilage and bone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KG KP KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2247158 Country of ref document: CA Ref country code: CA Ref document number: 2247158 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980706539 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 331517 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997907835 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997907835 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980706539 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997907835 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019980706539 Country of ref document: KR |